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Abstract 
 
 
Introduction 
Epidural analgesia provides satisfactory pain relief but is not without unwanted side 
effects or a significant failure rate. New multi-modal methods of delivering 
postoperative analgesia are being developed which aim to minimize side effects and 
enhance recovery. The aim of this thesis was to compare recovery following open liver 
resection (OLR) between patients receiving thoracic epidural (EP) or abdominal wound 
catheters plus patient-controlled analgesia (AWC-PCA).  
 
Method 
In order to address the aim of this thesis the following studies were developed: 
 
1. A systematic review of current modalities used for post-operative analgesia 
and current evidence for ERAS protocols in liver surgery. 
2. A systematic review and meta-analysis comparing outcomes between EP and 
AWC following open liver resection. This was performed according to PRISMA 
guidelines. 
3. An open-label randomized controlled trial allocating participants 1:1 to receive 
either EP or AWC-PCA within an enhanced recovery protocol. Primary outcome 
was length of stay (LOS). Secondary outcomes included functional recovery, 
pain scores, peak flow, vasopressor, fluid requirements and postoperative 
complications. 
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4. An assessment of the impact the two methods of analgesia have on the 
systemic inflammatory response by analysing and comparing cytokine levels at 
baseline (Day 0), Day 1 and Day 3 post-surgery in patients enrolled in the 
randomized controlled trial. 
 
Results 
For parts 1 & 2, five studies were included in the analysis. Pain scores were significantly 
better in the EP group on postoperative day 1 but comparable thereafter. The 
complication rate was worse in the EP group. Length of stay was comparable as were 
the other secondary outcomes. The included studies were of generally poor quality 
with only 2 randomised controlled trials specific to liver resection published.  
For part 3, between April 2015 and November 2017, 83 patients were randomized to 
EP (n=41) or AWC-PCA (n=42). Baseline demographics were comparable. No 
difference was noted in LOS (EP 6 days (3-27) vs. AWC-PCA 6 days (3-66), p=0.886). 
Treatment failure was 20% in the EP group vs. 7% in the AWC-PCA (p=0.09).  
Preoperative anaesthetic time was shorter in the AWC-PCA group, 49 min vs. 62 min 
(p=0.003). EP patients required more vasopressor support immediately 
postoperatively on day 0 (14% vs 54%, p=<0.001) and day 1 (5% v 23%, p=0.021). Pain 
scores were greater on day 0, afternoon of day 1 and morning of day 2 in the AWC-
PCA group however were regarded as low at all time points. No other significant 
differences were noted in IV fluid requirements, nausea/sedation scores, days to open 
bowels, length of HDU and postoperative complications. 
For part 4, thirty patients were recruited into the cytokine analysis section of this 
study, 17 in the AWC-PCA group and 13 in the EP group. Patients in the EP arm were 
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more likely to be ASA II and have a more extensive liver resection. Interleukin-9 and 
MIP-1 levels were significantly lower with time in the AWC-PCA arm. There were no 
other differences in cytokine levels between the two groups. 
 
Conclusion 
AWC-PCA was associated with reduced treatment failure and a reduced vasopressor 
requirement than EP up to two days post-operatively. Whilst the use of AWC-PCA did 
not translate into a shorter LOS in this study it simplified patient management after 
OLR. The inflammatory response was comparable. AWC-PCA was not inferior to EP 
when used in patients undergoing open liver resection. EP cannot be routinely 
recommended following open liver resections based on the evidence gathered 
throughout this study.  
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Chapter 1 
 
 
 
Introduction 
 
 
1.1 - The Scope of Liver Disease 
From a surgical perspective the liver is a frequent site for both benign and malignant disease. 
Benign liver lesions are common and can be difficult to differentiate from either primary or 
secondary liver malignancies. Benign liver lesions can frequently be asymptomatic and are 
often identified incidentally on radiological imaging for an unrelated problem 1. Although 
benign liver lesions tend to be asymptomatic, they can produce symptoms due to mass effect 
or present acutely with symptoms related to haemorrhage, necrosis or infection 1. The 
management of benign liver lesions can vary hugely from simple observation to complex 
hepatic resection or even liver transplantation 2, 3.  
 
The liver is also a common site for cancer to metastasize to, however, primary liver cancers, 
particularly hepatocellular carcinomas (HCCs), are becoming increasingly prevalent. Whilst 
multi-modal treatments for such cancers are increasing, surgery remains the mainstay of 
treatment when aiming to cure 4. 
 
Hepatocellular Carcinoma 
HCC accounts for approximately 90% of all primary liver malignancy and over 5% of all cancers 
and is currently the commonest cause of cancer related death 5, 6. It is more frequent in male 
patients and liver cirrhosis precedes the vast majority of cases. The risk of HCC developing in 
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these patients during their lifetime is increasing in part due to better medical management 
leading to increased survival. Curative management of HCC may be achieved by surgical 
resection, ablation or by transplantation 7, 8. Resection and ablation are readily available but 
are associated with a high tumour recurrence rate. In addition, de novo tumours are common 
as the diseased background liver parenchyma remains untreated. There is a consensus that 
liver transplantation offers the optimal long-term results for patients with HCC although this 
solution cannot be offered to all patients given the shortage of suitable organs and the 
restricted eligibility criteria 9, 10.  
In patients with no, or very minimal, cirrhosis the treatment of choice is liver resection as the 
liver remnant has a high capacity to regenerate allowing major resection to be performed. 
Perioperative mortality in these patients should be less than 1% with a morbidity of 
approximately 15% and overall survival in these patients is over 50% at 5-years 11. 
Liver resection in patients with a background of well-established liver cirrhosis is more 
challenging. Liver resection in these patients has several limitations. Recurrence rates remain 
high as background cirrhosis persists. Cirrhosis is a major risk factor for postoperative 
morbidity and the diseased liver requires a parenchymal sparing approach whereas 
oncologically, wider margins may be needed 12. Liver resection is however a valid treatment 
option in well selected patients, mainly Child-Pugh A or those with a low Model for End Stage 
Liver Disease (MELD) score with a single tumour and low morbidity has been reported in these 
groups. However, in Child-Pugh B and C groups, patients are at risk of liver failure after 
laparotomy alone 13. In some circumstances, resection is the only option when the tumour 
burden precludes transplantation. Additionally, with resection, there is no need for lifelong 
immunosuppression and donor grafts can be allocated to other patients on the waiting list 
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without other options. Offering liver resection as curative treatment is therefore reasonable 
and less complex than liver transplantation 14.  
In recent years, there has been increasing interest in the management of the future liver 
remnant with CT volumetry studies and increased use of pre-operative portal vein 
embolization to stimulate hypertrophy in the future liver remnant. This has become standard 
practice in colorectal liver metastases (CRLM) after extensive chemotherapy and in liver 
resection in patients with cirrhosis has been shown to reduce post-operative complications, 
reduce intensive care and total hospital  stay 15. Modification of surgical technique has also 
been linked to improved long-term survival with anatomical resection and wide margins 
favoured over parenchymal sparing surgery and limited margins due to tumour spread 
through microvascular invasion. This is however linked to tumour size and differentiation. 
Overall, when liver resection for patients with background cirrhosis is adopted the annual 
recurrence rate is reported to be 20 % with an estimated 5-year disease-free survival close to 
37 % and overall survival as high as 68% 16-18. 
 
Intrahepatic Cholangiocarcinoma 
Intrahepatic cholangiocarcinoma is the second most common primary liver cancer after HCC. 
These tumours arise from the peripheral intrahepatic biliary radicles, thus differentiating 
them from hilar (Klatskin) and distal common bile duct cholangiocarcinomas. This tumour is 
associated with a very poor overall prognosis and its incidence is increasing in the Western 
world. This is likely to be explained by improved identification of this tumour as well as 
increasing obesity related, non-alcoholic fatty liver disease or chronic hepatitis C infection 19, 
20. Surgical resection is, at present, the only curative treatment with only a debatable role for 
liver transplantation in small cholangiocarcinomas. As this tumour usually presents at an 
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advanced stage and can extend to major portal or hepatic vein branches a major resection is 
often required in 75-80% of cases 21. This includes resection of the common bile duct in over 
20% of cases and is associated with significant postoperative mortality 22. In addition, up to 
one-third of patients will have a contraindication to resection at laparotomy and of those 
resected 25% of patients will have an R1 or R2 resection 22, 23. The overall survival for patients 
undergoing R0 resection for intrahepatic cholangiocarcinoma is reported between 15-40% at 
5 years 24, 25.  
 
Peri-Hilar Cholangiocarcinoma (formerly known as Klatskin Tumour) 
Hilar cholangiocarcinoma is the most common type of cholangiocarcinoma, accounting for 
approximately 60% of all cases (intrahepatic, hilar and distal) 26, 27. These tumours most 
commonly present with jaundice with a tendency to local spread rather than distant 
metastases. Complete surgical resection is essential for long-term survival in patients 
presenting with hilar cholangiocarcinoma. However, patients frequently present with 
advanced disease involving the hepatic artery, portal vein and caudate lobe. This has meant 
that historically only about 20% of patients were deemed ‘resectable’. Consequently, major 
hepatic resections including bile duct and frequently vascular resection is required to achieve 
complete microscopic margin negative resection (R0) 28, 30. Morbidity associated with such 
major resections is understandably significant with rates as high as 75% reported with 
mortality rates between 5-15% 26, 31, 32. More recently, the use of preoperative portal vein 
embolization has been associated with a reduction in morbidity and mortality 33, 34. With 
resection, 5-year survival rates approaching 40% have been reported although recurrence 
rates have disappointingly been between 50-75%. The most important factor for recurrence 
is complete surgical excision, although tumour differentiation and lymph node involvement 
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are important biological predictors 28, 29, 35 - 37. For these reasons only a very few centres are 
advocating liver transplantation under strict criteria and as part of a multimodal therapeutic 
approach 38.  
 
Colorectal Liver Metastases 
Colorectal cancer is the most prevalent gastrointestinal malignancy and the second most 
frequent cause of cancer related death in the Western world 39. The liver is the most common 
site for metastasis and may be the only site in 30-40% of cases 40. At presentation, 20-25% of 
patients will have liver metastases and up to 50% will develop them following resection of the 
primary colonic tumour 41. At present, surgery remains the only treatment aimed at curing 
patients with CRLM 7. Originally only about 20% of patients were suitable for curative surgery 
at presentation, however, with improved preoperative staging, developments in systemic 
chemotherapy, new surgical strategies and multidisciplinary management of colorectal liver 
metastases (CRLM), increasing numbers of patients are being considered suitable. Resected 
CRLM are associated with a 5-year survival of 40-50% and a 10-year survival of 25%, although 
improved rates up to 67% at 5-years have been seen when combining surgery with 
chemotherapy 42. Criteria for resection have been relaxed and are now based on whether a 
macroscopically complete resection can be completed with an adequate future liver remnant. 
Currently, apart from patient fitness issues, the following are considered to be the only 
contraindications to resection: an untreatable primary tumour, bone or CNS metastases, 
widespread pulmonary or uncontrolled pulmonary disease and extensive nodal disease 7, 43. 
Typically, approximately 20% of patients are deemed to be resectable although a variety of 
strategies are now being employed to convert initially un-resectable patients to surgery. 
These include neo-adjuvant chemotherapy, portal vein embolization, two-stage 
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hepatectomy, redo hepatectomy, Associated Liver Partition and Portal vein ligation for Staged 
hepatectomy (ALPPS) and surgery for extrahepatic (usually oligometastatic) colorectal 
disease 44 – 50. However, median survival without treatment for CRLM is approximately 8 
months from presentation with only 3-5% of patients surviving 5 years, although this is 
dependent on disease burden 50, 52-54. 
 
Neuroendocrine and Non-Colorectal Liver Metastases 
Whilst colorectal cancer is the most common source of liver metastases, it is also possible for 
almost any solid tumour to metastasize there. These may be isolated liver metastases or 
associated with disseminated disease. Gastrointestinal tract cancers reach the liver via the 
porto-venous route whereas non-GI cancers spread via the systemic circulation and are thus 
usually indicative of disseminated disease. Non-colorectal liver metastases most commonly 
arise from the GI tract and can be broadly broken down into neuroendocrine and non-
neuroendocrine groups. Neuroendocrine tumours (NETs) are usually indolent with survival 
following resection of liver metastases associated with 5- and 10-year survival of 77% and 
50% respectively 54. Resection for neuroendocrine metastases is an increasingly accepted 
treatment strategy although much of the evidence for resection of non-colorectal non-
neuroendocrine liver metastases is based on retrospective studies. 
Resection for metastatic NETs leads to improved overall survival when compared with 
patients undergoing conservative treatment. Improved survival is also seen in patients having 
R1 and even R2 resections with 5-year survival as high as 70%. This is likely a result of reducing 
tumour burden which in addition has a benefit in symptom management 55-57.  
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Resection of liver metastases from a variety of primary tumours such as breast, renal, 
melanoma, ovary, lung and endometrium have all been reported. In general, surgical 
resection of these metastases is controversial with only poor-quality evidence supporting its 
role. In breast cancer, isolated liver metastases are uncommon and reported survival after 
liver resection is variable. It appears that survival in breast liver metastasis patients is closely 
linked to pre-operative chemotherapy response and surgery may be cyto-reductive rather 
than a curative procedure 58. With regards to other liver metastases from other sites, it is 
generally impossible to draw strong conclusions or recommendations for surgery with the 
evidence available 7.  
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1.2 - Enhanced Recovery After Surgery (ERAS) 
 
Approximately 2350 liver resections were performed in England in 2015, mainly for primary 
liver cancers and metastatic colorectal cancer with limited spread to the liver 59. Liver 
resection is a major and complex operation with an in-hospital death rate of 1% and a short-
term complication rate of roughly 20% although it remains the main treatment modality in 
such patients 60. Perioperative care for patients who are undergoing liver resection varies 
widely from unit to unit and surgeon to surgeon, with a lack of evidence base for much of the 
care patients receive. In the 1990s, Kehlet et al developed an ‘enhanced recovery pathway’ 
to improve outcomes in patients undergoing colorectal surgery and demonstrated faster 
recovery, reduced morbidity and shorter length of stay 61. Since then the concept of enhanced 
recovery after surgery (ERAS) has grown with these multi-modality pathways adopted by 
many surgical specialities led within the UK by pioneers such as the late Professor Kenneth 
Fearon from Edinburgh 62-64. Current evidence suggests a benefit in colorectal, urological and 
gastric surgery with a growing body of evidence for hepato-biliary surgery 65-67.  
ERAS pathways aim to streamline and standardise patient care by using varying methods to 
reduce surgical stress and ultimately reduce medical complications and improve patient 
recovery. These can be broken down into pre-, intra- and post-operative factors.  
Pre-operatively, ERAS Society recommendations are that patients receive counselling and 
education prior to surgery which improves patient involvement in decision making and can 
also improve motivation post-operatively, thereby increasing compliance with the pathway 
68, 69. In addition, avoidance of prolonged fasting and carbohydrate loading the evening before 
surgery has been shown to reduce insulin resistance as well as nausea, thirst and malaise. At 
present, the role of carbohydrate loading is well established in colorectal pathways although 
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the ERAS Society recommendations for liver surgery were only able give a weak 
recommendation based on currently available evidence 70-72. Nutrition is an eminently 
modifiable factor in patients scheduled for major surgery. Malnourished patients are at 
increased risk of complications postoperatively, and nutrition screening is an essential part of 
pre-operative workup. Patients with a low body mass index (BMI) or significant weight loss 
should receive nutritional supplementation in the week preceding surgery or, in severe cases, 
have surgery postponed whilst oral, enteral or even parenteral feeding is established. In 
addition, the use of antibiotic prophylaxis, venous thromboembolism prophylaxis and 
avoidance of long acting anxiolytics as a premedication are all recommended 67, 73, 74. 
Intraoperative factors that can be modified include the type of surgical incision and the 
surgical approach. Minimally invasive (laparoscopic) approaches to ‘minor’ liver resection, 
particularly in the left-lateral and anterior segments, have become the standard practice and 
have been demonstrated to reduce length of stay 75. However, the ORANGE-II study 
comparing open versus laparoscopic left-lateral sectionectomy had to be discontinued due to 
slow recruitment with no differences seen up to that point 76. The use of patient warming 
systems is recommended as intraoperative hypothermia is associated with increased blood 
loss and the need for transfusion as well as cardiac and non-cardiac complications, although 
evidence specific to liver surgery is lacking 77-79.  
Fluid management is another important aspect of perioperative care, with fluid overload 
being associated with increased peri-operative morbidity 80. Poor fluid management can also 
lead to postoperative ileus, delayed gastric emptying and delayed discharge from hospital 81. 
With regards to hepatic resection, fluid balance is particularly important with a variety of 
strategies used to minimise intraoperative blood loss and the ischaemia-reperfusion injury 
associated with hepatic transection. Such techniques include reverse Trendelenburg 
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positioning, restricted fluid intervention, maintenance of low CVP as well as surgical 
techniques such as Pringle’s manoeuvre and total vascular exclusion 82.  
Goal-directed fluid therapy refers to operative and immediate postoperative techniques 
aimed at modifying the haemodynamic status of patients undergoing major surgery. The 
ultimate goal of these techniques is to achieve optimal oxygen delivery while avoiding the 
deleterious complications associated with over- and under-resuscitation 83. The response to 
fluid can be assessed by measuring a number of cardiovascular parameters which vary during 
the ventilatory cycle. These include stroke volume, pulse pressure and systolic pressure which 
are more sensitive than blood pressure or pulse rate. The size of these variations also 
corresponds to the degree of hypovolaemia 84. The evidence regarding goal-directed fluid 
therapy shows that whilst it is a safe technique, the results have been mixed, although several 
meta-analyses showed a reduction in nausea, haemodynamic instability and a shorter 
hospital stay following major surgery 85. However, the benefit of goal-directed fluid therapy 
in the context of enhanced recovery appears to be less certain. This is likely to be because the 
patient is not hypovolaemic at induction of anaesthesia 84. Studies looking at goal-directed 
fluid therapy in patients who were hypovolaemic at induction found a reduction in length of 
stay compared to those not receiving fluid guided by oesophageal Doppler. The patients in 
this study also had fewer complications 86. An RCT comparing goal-directed fluid therapy using 
stroke volume variation to standard perioperative resuscitation in patients undergoing liver 
resection found less intraoperative fluid was given with goal-directed fluid therapy although 
postoperative complications were comparable. However, lower intraoperative fluid volume 
was independently associated with decreased morbidity in the entire cohort 83. However, 
other studies within colorectal surgery have found no such difference 87, 88. Despite this, the 
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use of goal-directed fluid therapy has been endorsed by the Enhanced Recovery Partnership 
and NICE 89, 90.    
 
Postoperatively, ERAS pathways focus on good post-operative analgesia, early mobilization, 
early reinstatement of diet and avoidance of nausea and vomiting. In one RCT, early 
reinstatement of food resulted in faster return of bowel function when compared with a more 
conservative ‘nil by mouth’ and enteral tube feeding regime 91. Similarly, the use of routine 
nasogastric tube placement has been associated with increased pulmonary complications 
including post liver resection and thus recommendations have been against its routine use 92, 
93. Postoperative analgesia is a paramount part of ERAS with many different modalities 
described. Traditionally, thoracic epidural has been considered the gold-standard for post-
operative analgesia. However, newer, multi-modality regimes are gaining popularity. 
Differing analgesic modalities are discussed in more detail later (Chapter 1.3). 
 
In hepatobiliary surgery, ERAS pathways have only been introduced relatively recently when 
compared with other surgical specialities. Multiple studies have been published comparing 
ERAS protocols with a more traditional care in liver surgery. This includes a combination of 
retrospective and prospective studies as well as RCTs. Almost all studies demonstrated a 
shorter length of stay with the use of an ERAS protocol following liver surgery. In addition, 
some RCTs demonstrated a significant reduction in complications 94, 95 whereas some non-
randomised studies have failed to show such a difference 96 - 103. The reduction in overall 
complication rate is generally thought to relate to a reduction in medical complications, with 
surgical complication remaining relatively constant 94. High compliance with ERAS protocols 
is associated with a reduction in length of stay and improved outcome and, conversely, poor 
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compliance is associated with increased readmission rates 104. Improving compliance rates 
with the ERAS protocols is obviously an important area for improvement, although even in 
ERAS protocols with low compliance (<70%) its use has been shown to improve short-term 
outcomes 105.  
 
 
The evidence regarding the use of ERAS pathways in liver surgery has largely been based on 
small studies which have lacked standardisation and therefore strong recommendations 
about their use have been difficult to make 67. In addition, compliance with the protocols in 
these studies is variable. However, in recent years a number of meta-analyses of the RCTs 
that have been published have demonstrated that ERAS pathways for liver resection are 
feasible, efficient and associated with a reduced length of stay and fewer complications 95, 106-
110. In reality, ERAS is now here to stay, and studies are needed that are specific to 
hepatobiliary surgery and will help to develop the various components of future ERAS 
protocols. In fact, one might argue that nowadays not implementing ERAS would be a 
departure from best practice following liver surgery.    
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1.3 - Post-Operative Analgesia  
 
Good post-operative pain control is essential after any major surgery and is a fundamental 
part of all ERAS protocols. It allows early mobilisation, helps to reduce post-operative 
complications, reduces patient distress, cost and length of stay 107, 111-115. There are numerous 
different methods of delivering postoperative pain relief, ranging from simple oral analgesics 
to regional anaesthesia. Following major abdominal surgery, the recognised ‘gold standard’ 
has generally been considered to be epidural analgesia 114.  
 
1.3.1 Epidural Analgesia 
Thoracic epidural analgesia (EP) is a major component of acute pain services and is primarily 
used to treat acute pain following major surgery. It is one of the most commonly utilised 
regional anaesthetic techniques with thoracic epidural consistently being shown to deliver 
good analgesia, improve post-operative pulmonary function, attenuate the stress response 
and allow early oral intake 114, 116, 117. It has also been well established that thoracic epidural 
with local anaesthetic reduces the length of postoperative ileus when compared to systemic 
opioids following abdominal surgery 118, 119, and it can also reduce pulmonary morbidity 120. 
The indication for thoracic epidural is generally considered to be moderate-to-large thoracic 
or upper abdominal incisions, and it is commonly used in combination with general 
anaesthesia in patients undergoing major abdominal surgery. Multiple studies have 
demonstrated the benefit of thoracic epidural, including the MASTER Anaesthesia trial. This 
was a large RCT which compared general anaesthesia and epidural plus postoperative 
epidural to IV opioid patient controlled analgesia (PCA) in high-risk patients with significant 
pre-operative comorbidity. It found a significant reduction in respiratory failure and improved 
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pain scores in the epidural group 121.  As such, it has been considered by many to be the gold 
standard for postoperative analgesia and has been incorporated into many ERAS protocols. 
There is also evidence that the use of EP is associated with significant reductions in 
postoperative morbidity and mortality, although subsequent RCTs have not confirmed this 
114. EP also has some potential advantages specific to liver surgery. This primarily relates to 
the sympathetic blockade associated with EP which can be used to maintain a low central 
venous pressure. This in turn can minimise blood loss and reduce transfusion requirements 
94.  
 
The choice of analgesia to be infiltrated with an epidural catheter can vary from local 
anaesthetic to opioids, or a combination of the two, with the decision usually dependent on 
patient factors. Use of local anaesthetic alone has shown comparable pain relief to a 
combined approach, but with a reduction in postoperative ileus 122. However, the use of local 
anaesthetic alone is often limited by hypotension although it can be used in patients with 
obstructive sleep apnoea or significant side-effects to opioids 120. There is no clear evidence 
that thoracic epidural with opioid alone is advantageous with the most common scenario 
being local anaesthetic and opioid used in combination. This method aims to use the two 
synergistically and reduce dose related side effects associated with larger doses of either drug 
alone 120.  
 
Whilst epidural analgesia has been shown to provide superior pain control when compared 
to other modalities, such as PCA alone, it is not without risk or side effects. Placement of a 
thoracic epidural catheter is generally considered to be of higher risk than a lumbar epidural 
although the risks with both techniques are considered to be small 120. One study analysing 
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4185 patients undergoing thoracic epidural found a complication rate of 3.1%, which included 
unsuccessful placement (1.1%), dural puncture (0.7%), radicular pain (0.2%) and peripheral 
nerve lesions (0.2%) 123. Another prospective study of 5628 patients found an overall epidural 
failure rate of 22%, with almost 70% of these removed due to accidental dislodgement 124. 
Whilst other publications have reported rates of epidural failure (inadequate analgesia or 
failed insertion) as high as 30% 112-115, 125. Other side effects include blockade of the 
sympathetic nervous system leading to hypotension requiring increased volumes of 
intravenous fluid and even vasopressors to maintain an adequate blood pressure 112-115. This 
is in addition to a growing body of evidence that increased volumes of intraoperative fluid 
can negatively impact on patient recovery 126. The insertion and ongoing management of 
epidurals is also time consuming and requires specialist input from an acute pain or ‘out of 
hours’ service, and even an on-call anaesthetist. This can obviously have a huge impact on 
service provision. Whilst the complications associated with epidural analgesia are rare, they 
can be potentially devastating such as epidural haematoma and abscess, although these are 
exceedingly rare 127, 128. This is particularly relevant in liver surgery where patients can develop 
a transient post-operative coagulopathy which potentially increases the risk of such 
complications. 
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1.3.2 Patient Controlled Analgesia 
Patient controlled intravenous opiate analgesia is a simple method to implement that is 
already commonly used for postoperative and acute pain. The pain relief provided at rest is 
good but not without unwanted side effects due to opioid use 129. Nausea and vomiting are 
frequently seen with intravenous opioid use, as are pruritus, constipation and confusion. 
However, less commonly, but more seriously, sedation and respiratory depression can also 
be seen. PCA has been shown to be more effective than the intermittent administration of 
intramuscular or subcutaneous morphine. However, when compared with epidural analgesia, 
both continuous and patient controlled, pain relief was inferior with PCA regardless of 
operation type, analgesic agent and method of pain assessment, although much of the 
literature is contradictory 130-133. Interestingly, an RCT comparing intravenous morphine PCA 
with epidural analgesia following cardiac surgery showed no difference in length of stay, pain 
scores, quality of recovery or morbidity with higher nausea scores in the epidural group 134. 
There are also RCTs published comparing the two techniques following gynaecological 
surgery showing no difference in pain relief 135. Schenk et al published a double blinded RCT 
following major spinal surgery which concluded that epidural analgesia provided superior 
pain control with a greater patient satisfaction 136. Similar studies in thoracic surgery, 
transplantation and general surgery have also showed epidural analgesia to be superior 137. 
Poor postoperative pain control is also associated with impaired pulmonary function 
following major surgery. Panaretou et al demonstrated improved pulmonary function in 
patients receiving epidural analgesia compared to PCA in patients with chronic obstructive 
pulmonary disease undergoing open infra-renal abdominal aortic aneurysm repair 138. A 
meta-analysis of RCTs has subsequently been performed demonstrating that pain relief with 
epidural analgesia is superior to that provided by opioid PCA regardless of operation 130. 
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Recently, several studies have been published comparing epidural with PCA following liver 
resection. One retrospective study found largely comparable outcomes between the two 
groups although the epidural group underwent more major resections and required less IV 
analgesia than the PCA group 139. A randomised trial comparing epidural with PCA following 
major hepato-pancreato-biliary surgery found improved pain relief, better patient experience 
and less opiate use in the epidural group with comparable length of stay and complications 
140.  
 
1.3.3 Intrathecal Morphine 
Intrathecal morphine has been used for postoperative analgesia since the 1970s, although its 
popularity was limited due to concerns regarding high rates of respiratory depression 141-143. 
More recently, its popularity has increased again with the use of smaller doses in an attempt 
to limit such side effects. Within the field of hepatobiliary surgery, intrathecal morphine has 
been compared to numerous other methods of delivering postoperative analgesia with mixed 
results. Several studies have compared epidural to intrathecal morphine following 
hepatectomy and found no difference in resting or dynamic pain scores 144, 145, although 
improved pain scores were seen when epidural and intrathecal morphine were combined and 
compared to a group receiving only intrathecal morphine 146. Length of stay was also found 
to be shorter in one RCT comparing epidural to intrathecal morphine 144. Several RCTs have 
also compared intrathecal morphine to either placebo or PCA, with both finding improved 
pain scores albeit without differences in complication rate between PCA and intrathecal 
morphine 147 - 148. Interestingly, Dichtwald et al compared preoperative intrathecal morphine 
to intraoperative intravenous remifentanil during hepato-pancreatic surgery and found that 
pain control was superior in the intrathecal morphine group up to 3 days postoperatively 149. 
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However, Kasivisvanathan et al found in their prospective study that intrathecal morphine 
plus a fentanyl PCA was associated with worse pain scores, shorter length of stay and less 
vasopressor support than epidural. However, they noted that intraoperative blood loss was 
higher than the thoracic epidural group 150.   Sakowska et al compared patients undergoing 
hepato-pancreato-biliary surgery who received either thoracic epidural, intrathecal morphine 
plus opiate PCA or PCA alone. This study demonstrated a reduced incidence of postoperative 
hypotension, reduced intravenous fluid requirement, shorter length of stay and fewer 
respiratory complications in favour of intrathecal morphine when compared to thoracic 
epidural 151. 
A further RCT comparing local anaesthetic infiltration with 0.5% ropivacaine via a wound 
catheter with intrathecal morphine followed by continuous infusion of fentanyl found that 
pain scores were better in the intrathecal morphine group for the initial 12 hours 
postoperatively but comparable beyond this. However, the time to first pass flatus was earlier 
in the wound catheter group 152.   
 
1.3.4 Transversus Abdominis Plane (TAP) and Rectus Sheath Blocks 
Regional anaesthesia of the abdominal wall can provide excellent pain relief following a 
variety of abdominal operations. It has however been noted that these do not provide 
analgesia to the abdominal viscera and therefore must be used as part of a multimodal 
technique. Historically, these blocks were performed using anatomical landmarks and 
clinically feeling ‘pops’ as the needle crossed the fascial planes. More recently, ultrasound has 
been increasingly used to visualise correct needle placement and the spread of local 
anaesthetic 153. Specific nerve blocks that have been described include the rectus sheath 
block. This aims to block the terminal branches of the 9-11th intercostal nerves, which run 
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between the internal oblique and transversus abdominis muscle before piercing the posterior 
wall of the rectus abdominis muscle. They terminate in an anterior cutaneous branch 
supplying the skin of the umbilicus.  
The TAP block aims to block the sensory nerves of the abdominal wall before they enter the 
musculature to innervate the abdomen by infiltrating with a large volume of local anaesthetic 
into the plane between the transversus abdominis muscle and the internal oblique. This plane 
contains the nerves from T7 to L1. This was initially described using the lumbar ‘triangle of 
Petit’ which is bound by the external oblique anteriorly, the latissimus dorsi posteriorly and 
the iliac crest inferiorly. Good postoperative analgesia and reduced opioid requirements for 
up to 48-hours post-operatively have been demonstrated for multiple surgical specialities 
including colorectal surgery, prostatectomy, hysterectomy and other gynaecological surgery 
154. Complications following such blocks include failure, intravascular injection or entry into 
the peritoneal cavity risking bowel or visceral injury, although this risk is minimised with 
ultrasound guidance 153. Literature comparing epidural analgesia to TAP blocks is also 
conflicting. Several studies have shown that TAP blocks are inferior to epidural 155, with other 
showing comparable outcomes 156. Notably, some of these studies were underpowered to 
detect small outcomes.  
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1.3.5 Wound Catheters in Abdominal Surgery 
The main limitation of rectus sheath and transversus abdominis plane blocks was the duration 
of action with even the longest acting local anaesthetics being effective for 24 hours. To 
prolong the duration of action, catheters allowing the continual infusion of local anaesthetics 
have been developed. The use of wound catheters as a method of providing post-operative 
pain relief has been described in many different surgical specialities including colorectal 
surgery, gynaecology and urology. An initial meta-analysis showed that the use of these 
wound catheters to infuse local anaesthetic was associated with improved pain scores, 
improved satisfaction, reduced opioid consumption and earlier discharge when compared to 
saline/water infusion 157.  A further meta-analysis combining data from RCTs in multiple 
specialities performing abdominal surgery showed no difference in pain scores at rest after 
48 hours, although there was a non-significant trend towards improved pain scores on 
movement in the epidural group 158. However, this was a heterogeneous group of studies and 
the authors recommended further procedure-specific RCTs, including broader measures of 
recovery, in order to compare the overall efficacy of wound catheters. In hepato-pancreato-
biliary surgery, the evidence surrounding their use is extremely limited with only three RCTs 
published, with two from the same institution (Edinburgh Royal Infirmary, Scotland, UK), and 
a small number of retrospective studies.  
Specifically, in the context of liver surgery, there are three randomised studies comparing 
epidural with wound catheters 114, 159, 160. Two of these studies demonstrated a shorter length 
of stay/functional recovery with wound catheters although one study demonstrated inferior 
pain scores with wound catheters and the other comparable pain relief. Neither study showed 
any difference in co-morbidity 114, 159. A randomised, open label, non-inferiority trial (POP-UP 
trial) demonstrated that continuous wound infiltration is not inferior to epidural analgesia 
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within the enhanced recovery setting in hepato-pancreato-biliary surgery although this study 
included pancreatic surgery 160. A further multicentre, blinded RCT compared wound 
catheters and PCA to PCA alone following open liver resection and found that the use of 
wound catheters reduced opioid requirements, pain and length of stay 161. The current 
evidence comparing wound catheters and epidural in hepato-pancreato-biliary surgery is 
covered in chapter 2.  
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1.4 - Anatomy of the Anterior Abdominal Wall 
An understanding of the anatomy of the anterior abdominal wall is essential for the correct 
placement of wound catheters. The anterior abdominal wall is the area between the costal 
margins and xiphoid process of the sternum superiorly, the inguinal ligaments and pelvic 
bones inferiorly and the mid-axillary lines laterally. The anterior abdominal wall is made up of 
three layers of muscle each surrounded by a fascial sheath or aponeurosis. These muscles are 
the external oblique, internal oblique and the transversus abdominis 162. The paired rectus 
abdominis muscles are located either side of the midline and are enclosed by the rectus 
sheath, made up of aponeuroses of the other three muscles. The anterior layer of the rectus 
sheath is formed by the aponeuroses of the external oblique and half of the internal oblique 
with the posterior layer formed by the aponeuroses of the other half of the internal oblique 
and the transversus abdominis. One third of the way between the umbilicus and pubic 
symphysis all the aponeuroses condense and form an anterior layer only leaving just the 
transversalis fascia and peritoneum posteriorly. This transition is known as the arcuate line. 
In the midline all layers of the rectus sheath join to form the linea alba 163. The transversus 
abdominis plane exists between the internal oblique and transversus abdominis muscles and 
carries the neurovasculature of the anterior abdominal wall 164. Correct placement of wound 
catheters within this layer of the abdominal wall is essential if effective blockade of the nerves 
is to be achieved, thereby providing good analgesia. See Figure 1. 
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Figure 1 – Anatomy of the Anterior Abdominal Wall 
 
 
1.5 - Nerve Supply of the Anterior Abdominal Wall 
The transversus abdominis plane contains the anterior rami of the lower six thoracic nerves 
(T7 to T12) as well as the first lumbar nerve. These nerves supply the skin, muscles and parietal 
peritoneum. The thoracic nerves from T7 to T11 enter this neurovascular plane at the costal 
margin and travel through it to enter the posterior wall of the rectus sheath and continue as 
anterior cutaneous branches supplying the overlying skin. Thoracic nerves T7 to T9 supply the 
skin superior to the umbilicus with T10 supplying the umbilicus and T11, T12, iliohypogastric 
nerve and ilioinguinal nerve supplying the skin to the umbilicus 165. 
The iliohypogastric nerve arises from the L1 nerve root and runs in the plane between the 
internal oblique and transversus abdominis muscle. It subsequently pierces the internal 
oblique to lie between the internal oblique and external oblique and gives off cutaneous 
branches to supply the skin of the inguinal region. 
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The ilioinguinal nerve also arises from the L1 nerve root and runs inferior to the iliohypogastric 
nerve, pierces the transversus abdominis muscle at the level of the iliac crest and runs 
medially in a deeper plane than the iliohypogastric nerve. This nerve supplies the medial 
aspect of the thigh and the anterior scrotum or labia 163-165. See Figure 2. 
 
Figure 2 – Nerve Supply of the Anterior Abdominal Wall 
 
 
 
The three randomised studies comparing wound catheters with epidural have placed wound 
catheters in to the posterior rectus sheath and transversus abdominis plane to block these 
nerves. The most common placement location for these catheters is illustrated in Figure 3. 
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Figure 3: Location of Wound Catheter Placement. A) For ‘Reverse L’/Subcostal Incision 
(Transversus abdominis plane laterally and posterior rectus sheath medially with an optional 
catheter in the left posterior rectus sheath. B) For Midline Incision (bilateral posterior rectus 
sheath catheters). 
 
 
1.6 - Evidence in Hepato-Pancreato-Biliary Surgery 
Epidural analgesia is used routinely during HPB surgery.  It has been shown to allow earlier 
mobilisation plus a swifter recovery 166.  These advantages have resulted in this analgesic 
modality becoming part of enhanced recovery programmes, both in colorectal and liver 
surgery 94, 167. Nevertheless, there is concern of potential serious complications such as 
epidural abscess and haematoma. Whilst these are rare, the postoperative coagulopathy 
sometimes associated with liver resection has sometimes been thought to increase this risk 
168. In addition, epidural associated hypotension may lead to: 1. increased fluid requirements 
intra and postoperatively during liver resection 114. 2. increased need for postoperative 
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inotropes and subsequent need for level 2 facilities (HDU). These issues have led to the use 
of other modalities of postoperative anaesthesia such as local anaesthetic infiltration via 
wound catheters. These techniques have shown a significant reduction in opioid use following 
surgery, which is the obvious alternative to epidural 125, especially with use of continuous 
infusion of local anaesthetics 157.  Wound catheters are being increasingly used in liver surgery 
with satisfactory pain relief 114, 159, 169. A recent meta-analysis comparing epidural with wound 
catheters in patients undergoing open abdominal surgery found comparable pain scores 
between the two groups 158.  Nevertheless, there is a paucity of data comparing epidural 
analgesia and wound catheters, in particular during liver surgery.  
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1.7 - Effect of Analgesia on the Systemic Inflammatory Response 
Inflammation can be defined as the reaction of the host to injury and brings about the release 
of vasoactive mediators such as histamine and leukotrienes from mast cells. This causes 
vasodilatation, increased vascular permeability and leads to the typical signs of inflammation, 
redness (rubor), heat (calor) and the subsequent tissue oedema causing swelling (tumour). 
Interaction of these inflammatory mediators with the sensory system leads to pain (dolor).  
Significant tissue injury, such as that caused by surgery, leads to a systemic response or acute 
phase reaction which triggers two initial pathways 170. The first is the release of cytokines and 
inflammatory mediators from injured tissues and the second is the stimulation of afferent 
neurones carrying information to the central nervous system. These two systems are not 
independent from each other and it is important to note that there is significant interaction 
between them. These pathways both activate the sympathetic system in the brainstem and 
the release of corticotrophin releasing hormone from the hypothalamus with a positive 
feedback system between the two 171. This neuroendocrine response culminates in the 
release of cortisol, growth hormone and prolactin from the anterior pituitary and vasopressin 
from the posterior pituitary, as well as secretion of catecholamines from the adrenal medulla. 
The release of cortisol and catecholamines stimulate glycogenolysis and gluconeogenesis as 
well as reduced insulin secretion and increased insulin resistance. Cortisol also stimulates 
catabolism of protein and stored fat to ultimately produce more energy.  
As described previously, the systemic inflammatory response (SIR) following surgery is a 
response that, mediated by activated leucocytes, fibroblasts and endothelial cells, produces 
a number of low molecular weight proteins called cytokines. These molecules are essential 
for cell-signalling and act on surface receptors of target cells to bring about their effect. The 
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earliest mediators of inflammation are interleukin (IL)-1, IL-6 and tumour necrosis factor 
(TNF)-, with many other cytokines being subsequently released. Release of cytokines at the 
site of injury helps to coordinate the response to injury and induces neutrophil chemotaxis. 
Cytokines released locally include IL-1, IL-6 and TNF-. These cytokines also cause lymphocyte 
proliferation, activate neutrophils and induce fever. The inflammatory response leads to 
macrophages, monocytes and polymorphonuclear granulocytes being recruited to the injured 
area. This systemic inflammatory response is essential for structural and functional repair of 
damaged tissues. However, excessive inflammation can heighten tissue damage 170.  
Major surgery leads to a variety of metabolic, neuroendocrine and immune responses, which 
aim to maintain physiological stability and promote healing 172. This response to the trauma 
of surgery leads to the activation of macrophages and neutrophils, which are produced as a 
response to pro-inflammatory cytokines, including TNF-α and the interleukins (IL) such as IL-
1 and IL-6 173, 174. These cytokines subsequently alter the level of circulating acute phase 
proteins such as CRP, albumin and fibrinogen 175. It has been reported that the circulating 
levels of cytokines and acute phase proteins corresponds to the size of the systemic 
inflammatory response. This inflammatory response is particularly relevant in liver surgery as 
pro- and anti-inflammatory cytokines coordinate a range of physiological and pathological 
pathways such as inflammation, organ failure and liver regeneration 176 – 178.     
 
One of the most important cytokines to be released initially is IL-6 and this is the most 
frequently measured cytokine when investigating the SIR following surgery. This is often 
undetectable preoperatively, although rises quickly before reaching a peak plasma 
concentration at 24 hrs postoperatively 179. However, there are multiple other cytokines, with 
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a variety of pro- and anti-inflammatory properties which have been reported in a variety of 
surgical specialities. These studies show that whilst the response pattern is generally similar, 
the size and duration of that response can be highly variable and dependent on many factors. 
Two of these factors include the type of surgical procedure, with larger, more extensive 
procedures producing a larger SIR and the development of postoperative complications also 
leading to a bigger response 180-182. Also, of relevance to hepatic surgery is the impact tissue 
ischaemia and subsequent reperfusion has on increasing the cytokine response. In liver 
resection use of Pringle’s manoeuvre is common and produces such an effect 183, 184.  
 
There have been multiple studies looking at differing methods of pain relief and their 
influence on the inflammatory response. Differing methods of post-operative pain relief have 
been shown to modulate this inflammatory stress response, which may lead to improved 
outcomes. One of the most frequent methods of delivering post-operative pain relief is 
epidural analgesia and multiple studies, in a variety of surgical specialities have examined 
their impact on the systemic inflammatory response.  
Initial studies compared outcomes between patients undergoing surgery with a general 
anaesthetic or general anaesthetic combined with intraoperative epidural. Several RCTs have 
been published, all demonstrating that epidural reduces the systemic inflammatory response. 
Dong et al compared outcomes following radical surgery for epithelial ovarian cancer. Lower 
levels of IL-1 and IL-8 and increased levels of IL-10 and IFN- were noted in the GA + EP group 
with the authors concluding that combined general anaesthetic (GA) and thoracic epidural 
(EP) promoted anti-tumorigenic cytokine responses 185. Similarly, Hadimioglu et al compared 
the same groups undergoing renal transplantation in non-diabetics. A partly attenuated stress 
response was noted with the combined GA/EP approach with TNF- and IL-6 levels being 
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significantly higher in the GA alone group (PCA for postoperative analgesia) 186. In general 
surgery, intraoperative epidural was compared with intravenous opioid analgesia 
intraoperatively in patients undergoing major abdominal surgery with both groups receiving 
patient-controlled epidural postoperatively. The IFN-/IL-10 ratio was significantly higher in 
the epidural group from 2 hours to 1 day postoperatively. No differences were seen with IL-
2. In this study, the use of Intraoperative EP reduced the stress response and prevented 
stress-induced perioperative impairment of pro-inflammatory lymphocyte function 187.  
The majority of RCTs have compared epidural with systemic opioids, usually in the form of 
patient-controlled analgesia. Fant et al compared patients undergoing radical retropubic 
prostatectomy. This study found that cortisol and glucose levels in the initial period following 
surgery were significantly higher with PCA as was IL-17 at 24 and 72 hours. However, IL-6 and 
TNF- were comparable. This showed that although epidural reduced the early postoperative 
stress associated with surgery, it did not reduce the acute inflammatory response 188. Two 
studies within colorectal surgery showed slightly variable results with Day et al demonstrating 
no differences in circulatory IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IFN-, TNF- or VEGF at any time 
point, although cortisol and glucose were lower at 3 hours post-surgery 189. However, another 
study found that only IL-4 and IL-10 were higher at all time points with PCA, suggesting that 
EP attenuates the stress response 190. Gu et al found the combination of total intravenous 
anaesthesia (TIVA) with intraoperative epidural and postoperative patient-controlled 
epidural inhibited the stress response with no significant increase in cortisol, IL-17 and IL-6 
191. Hepatobiliary surgery patients undergoing hepatectomy for HCC had significantly lower 
IFN- and IL-4 with GA and EP and IL-17 levels remaining significantly lower up to day 7 post-
surgery when compared to GA and PCA 192. 
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Only one RCT compared intraoperative intravenous lidocaine to epidural and placebo in a 
blinded study following colorectal surgery with all patients receiving postoperative analgesia 
via EP. Significant differences were noted in IL-6 and IL-8 between the 3 groups with the least 
increase in pro-inflammatory cytokines seen with intraoperative thoracic epidural 193. 
A double blind RCT compared intraperitoneal infiltration of ropivacaine to saline placebo, 
although both arms in this study also received epidural postoperatively. The ropivacaine was 
infiltrated pre-dissection and continued up to 3 days following surgery via wound catheters. 
IL-6, IL-8 and TNF- were all diminished at 8 and 20 hours, although only IL-6 was reduced at 
48- and 72-hours post-surgery 194. Fiorelli et al also randomised patients to receive either 
bupivacaine or saline wound infiltration via wound catheters up to 48 hours following lung 
resection with a muscle-sparing thoracotomy. Bupivacaine infiltration significantly decreased 
levels of IL-6, IL-10 and TNF- when compared to placebo 195. The only study to compare 
postoperative epidural with wound catheters following liver surgery was the LIVER-2 study 
which found that levels of IL-1, IL-6, IL-8, IL-10 and TNF- peaked on day 1 from baseline and 
had improved but were not back to baseline by day 3. However, no differences in 
inflammatory response were noted between the 2 groups 159. Interestingly, in abdominal 
surgery one study was able to associate an IL-6 level of greater than 432 pg/ml with an 
increased risk of post-operative complications following major abdominal surgery 196. 
 
There is some evidence that the use of local anaesthetics may be able to modulate the 
systemic inflammatory response, with some laboratory studies having shown that amide local 
anaesthetics such as lidocaine or bupivacaine inhibit IL-1 in a dose-dependent manner 170. 
As IL-1 stimulates chemotaxis, degranulation and phagocytosis by acting on 
polymorphonuclear granulocytes, inhibition of these effects by local anaesthetics may 
  32 
contribute to an anti-inflammatory effect. TNF-, IL-8 and granulocyte-macrophage colony 
stimulating factor (GM-CSF) are often described as ‘priming’ agents when they are exposed 
to polymorphonuclear granulocytes. This ‘priming’ is an essential regulatory mechanism 
involved in the overstimulation of inflammatory pathways, which can lead to tissue damage. 
Local anaesthetic agents have been shown to block priming of polymorphonuclear 
granulocytes and it is possible that this activity contributes to their anti-inflammatory actions.   
 
The volume of evidence regarding the impact that different analgesic modalities have on the 
systemic inflammatory response is growing. As with other aspects of hepatobiliary surgery, 
the evidence base specific to this branch of surgery is limited, as is the evidence base looking 
at the impact of wound catheters on the systemic inflammatory response. Indeed, there is 
only one paper assessing the impact of wound catheters on the inflammatory response in 
liver surgery 159. As such, this is an important area for further investigation. It is necessary to 
establish the impact that wound catheters have on the systemic inflammatory response prior 
to their recommendation over thoracic epidural.
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Chapter 2 
 
Wound Catheters in Open Liver Resection 
 
2.1 Introduction 
As described in Chapter 1 there is a paucity of data regarding the efficacy of wound catheters 
within hepato-biliary surgery with only limited studies published to date. To further evaluate 
this scenario, a systematic review and meta-analysis of the available literature regarding the 
use of wound catheters in liver surgery was performed comparing results between local 
anaesthetic infiltration via wound catheters versus epidural analgesia in patients undergoing 
open liver resection.  
 
2.2 Methodology 
Randomized and cohort studies (irrespective of language, country of origin, hospital, blinding, 
sample size or publication status) that compared the use of local anaesthetic infiltration via 
wound catheters with epidural catheters for elective liver resection were included. The 
Cochrane Colorectal Cancer Group Controlled Trials Register, the Cochrane Central Register 
of Controlled Trials in the Cochrane Library, MEDLINE, Embase and Science Citation Index 
Expanded were searched for articles published up to January 2018 using the medical subject 
headings (MeSH) terms ‘epidural, wound catheters, local anaesthetic infiltration and liver 
resection’. Equivalent free-text search terms, such as ‘epidural analgesia, local anaesthetic 
infiltration’, were used in combination with ‘liver resection’ and ‘hepatectomy’. The 
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references from the included studies were searched to identify additional studies comparing 
the two techniques.  
Studies were restricted to those on human subjects; those reporting at least two study groups 
epidural and wound catheters in patients undergoing open liver resection for benign and 
malignant conditions including cirrhotic livers and those undergoing resection for living donor 
liver transplantation. Studies that failed to fulfil the above inclusion criteria were excluded 
from this study. Exclusion criteria were the following: review articles, letters, editorials, 
comments, case reports and studies reported from the same research group with the same 
data source. 
 
Outcome Measures 
The primary outcome measures were pain scores on postoperative days 1, 2, and 3. 
Secondary outcome measures were hospital stay, time to opening bowels, overall 
complications and analgesia-specific complications. To calculate opiate requirements, opiate 
doses were converted to morphine-equivalent doses. 
 
Definitions  
Overall, complications were defined as those directly related to the liver resection and to 
general ones such as renal, cardiorespiratory, pleural effusions, wound infections, deep vein 
thrombosis and pulmonary embolism.  
Pain scores used were an 11-point scale (0-10). Those studies using a 101-point scale (0-100) 
were converted to an 11-point scale. Pain scores from comparable time points were used 
from each study. 
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Data extraction and quality assessment 
Studies were systematically identified and data were extracted. The accuracy of the extracted 
data was further adjudicated as required.  
 
Statistical analysis 
Statistical analysis was performed using Review Manager Version 5.2 software (Cochrane 
Collaboration). The risk ratio (RR) with 95% confidence interval (CI) was calculated for binary 
data, and the mean difference with 95% CI for continuous variables. When median and range 
were reported instead of mean and variance, their mean and variance was calculated based 
on the methods described by Hozo and colleagues 197.  Random and fixed-effects models were 
used to calculate the combined outcomes of both binary and continuous data 198, 199. In cases 
of heterogeneity, only the results of the random-effects model were reported. Heterogeneity 
was explored using the X2 test, with significance set at P < 0.05. Low heterogeneity was 
defined as an I2 value of 33% or less 200. If standard deviation was not provided, it was 
calculated according to the guidelines of the Cochrane Collaboration 201. This process involved 
assumptions that both groups had the same variance, which may not have been true, and 
variance was estimated either from the range or from the P value. Forest plots were used for 
graphical display of the results.  
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2.3 Results  
Five studies fully met the inclusion criteria and formed the basis of this meta-analysis (see 
Figure 4) 114, 159, 202-204. These included two randomised studies, one prospective study and 
two retrospective studies. All five studies combined had 798 patients; 215 patients were in 
the epidural analgesia group and 583 patients in the wound catheter group. The 
characteristics of the included studies are detailed in Table 1. Importantly 3 studies 114, 203, 204 
provided a PCA in addition to AWC for postoperative pain relief in the AWC arm whereas the 
other 2 studies did not 159, 202. The quality of the included studies is detailed in Tables 2 and 3. 
Pooled data were analysed by combining the results of the 5 studies.  
 
Primary outcome measures 
Postoperative day 1 (POD) pain scores  
Data from 2 studies were included in this analysis 114, 204. There was no significant 
heterogeneity between these trials (Tau2=0.00, Chi2=0.79, df=1 (P=0.37), I2=0%. In a random-
effects model, the pain scores were significantly higher in the wound catheter group with a 
mean difference of -0.90 [-1.29, -0.52] Z=4.61 (P<0.00001).  See Figure 5. 
 
Postoperative day 2 (POD) pain scores  
Data from two studies was included in this analysis 114, 204. There was no heterogeneity among 
the trials (Tau2=0.00, Chi2=0.03, df=1 (P=0.86), I2=0%).  In a random-effects model, the pain 
scores were similar between the 2 groups on day 2 (MD -0.29[-0.65, 0.07], Z=1.58 (P=0.11)). 
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Figure 4 - PRISMA Flow Diagram 
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Records after duplicates removed 
(n = 435) 
Titles screened 
(n = 435 ) 
Papers excluded on title 
(n = 176) 
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abstract  
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Table 1 – Summary of interventions 
Reference Operatio
n 
Incision Analgesia 
Type 
n per  
group 
Age Intervention Drugs Administered ERP Additional drugs 
Revie et al. Open 
Liver 
resection 
Right 
Subcostal 
Wound 
Catheter 
33 60 Dual wound 
catheter placed 
by surgeon in 
transversus 
abdominis plane 
and post. Rectus 
sheath 
20ml 0.25% levobupivacaine 
bolus followed by continuous 
0.375% levobupivacaine at 
4ml/hr for 48hr 
Yes Paracetamol 1g 
QDS 
Ibuprofen 400mg 
TDS 
Oxycodone 10mg 
PRN 
IV morphine PCA 
Epidural 31 60 T7-8 Epidural Continuous 0.1% bupivacaine 
and 2 mcg/ml fentanyl at 7-
10ml/hr 
Soliz et al. Open 
Liver 
Resectio
n 
Right 
subcostal or 
bilateral 
subcostal 
Wound 
Catheter 
72 53.7 Dual wound 
catheters above 
the fascia 
Bolus of 10ml 1:1 1% lidocaine 
and 0.25% bupivacaine. 
Continuous 4ml/hr 0.5% 
ropivacaine 
No IV morphine PCA 
Epidural 71 54.3 T6-10 Epidural 0.075% or 1 % bupivacaine 
with hydromorphone 5mcg/cc 
or 2mcg/cc 
Stefancic et 
al. 
Open 
liver 
Resectio
n 
Right 
Subcostal 
Wound 
Catheter 
15 - 30cm long 
multiholed 
catheter above 
fascia along 
wound length 
10ml levobupivacaine bolus. 
8ml/hr 0.25% levobupivacaine 
for 48hr 
No IV Diclofenac 
75mg BD  
IV morphine PCA 
Epidural 14 - T8-11 Epidural Levobupivacaine 0.5% 5-7ml 
and 100mcg fentanyl  bolus. 
Continuous 0.125% 
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levobupivacaine and fentanyl  
2mcg/ml at 6ml/hr 
Wong –Lun-
Hing et al. 
Open 
Liver 
Resectio
n 
Reverse L Wound 
Catheter 
429 63 Dual wound 
catheter placed 
by surgeon in 
transversus 
abdominis plane 
and post. Rectus 
sheath 
10ml bolus of 0.25% 
bupivacaine. Continuous 
0.25% bupivacaine at 3ml/hr 
for 72hr 
No Morphine/Fentan
yl PCA 
PO paracetamol, 
NSAID and opioid 
available to all 
patients 
Epidural 69 63 T5-12 Epidural 20ml 0.25% bupivacaine bolus. 
0.1% bupivacaine and 
2mcg/ml fentanyl at 5-15ml/hr 
Hughes et 
al. 
 
 
 
Open 
Liver 
Resectio
n 
Right 
Subcostal 
Wound 
Catheter 
 
49 62.8 Dual Limb 12.5cm 
in transversus 
abdominis plane 
and posterior 
rectus sheath 
40ml 0.125% levobupivacaine 
bolus. Infusion of 0.375% 
levobupivacaine at 4ml/hr for 
48hr 
 
 
 
 
Yes 
1g Paracetamol 
QDS 
Epidural 44 62.6 T8-9 Epidural 4ml 2% lidocaine followed by 
10ml levobupivacaine with 
100mcg fentanyl. Infusion of 
0.1% levobupivacaine with 
2mcg/ml fentanyl 
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Postoperative day 3 (POD) pain scores  
Data from 2 studies were included in this analysis 114, 204. There was significant heterogeneity 
among the trials (Tau2=0.59, Chi2=5.60, df=1 (P=0.02), I2=82%).  In a random-effects model, 
the pain scores were similar between the 2 groups on day 2 (MD -0.33 [-0.84, 1.49], Z=0.55 
(P=0.58)).   
 
Secondary outcome measures 
Time to opening bowels  
Data from 3 studies were included in this analysis 159, 203, 204. There was heterogeneity amongst 
the included studies (Tau2=0.59, Chi2=9.11, df=2 (P=0.01), I2=78%). In a random-effects 
model, time to opening bowels was similar between the 2 groups (MD 0.24[-0.74,1.23]; 
Z=0.48 (P=0.63)). 
 
Opioid use  
Data from 3 studies were included in the analysis 159, 202, 203. There was heterogeneity amongst 
the included studies (Tau² = 1403.39; Chi² = 15.56, df = 2 (P = 0.0004); I² = 87%). In a random-
effects model, the opioid use was similar between the 2 groups (MD -6.46 [-56.60, 43.69] Z = 
0.25 (P = 0.80)). 
 
Overall complications  
Data from 3 studies were included in this analysis 114, 159, 202. There was no heterogeneity 
amongst the included studies. In a fixed effect model, the overall complication rate was higher 
in the epidural group, 52% versus 30% (RR 1.39 [1.13, 1.72]; Chi² = 0.60, df = 2 (P = 0.74); I² = 
0%; Z=3.06 (P=0.002)). See Figure 6. 
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Figure 5: Forest Plot of Postoperative pain score - day 1 
 
 
 
 
Length of hospital stay 
Data from four studies were included in the analysis 114, 159, 202, 204. There was no heterogeneity 
amongst the included studies. In the fixed-effect model, the length of hospital stay was similar 
in both groups (MD 0.78[-0.35, 1.91] X2=0.07, df=3 (P=0.99), I2=0%; test for overall effect 
Z=1.35(P=0.18)).  
 
Figure 6: Forest Plot of Overall Complications 
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Table 2 – Characteristics of Included studies 
Study Year Centre Inclusion 
Period 
Country Number of 
epidural 
patients 
Number of 
wound 
catheter 
patients 
Newcastle 
Ottawa Score 
Revie et al 2012 Single Aug 2009 – July 
2010 
UK 31 33 See Table 3 
Wong-Lun-Hing 
et al 
2013 Single July 2004 – July 
2011 
UK 69 429 7 
Stefancic et al 2013 Single 2012 - 2013 Croatia 14 15 4 
Soliz et al 2012 Single July 2005 – July 
2010 
USA 71 72 5 
Hughes et al 2015 Single Dec 2012 – 
June  2014 
UK 44 49 See Table 3 
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Table 3 – Quality Assessment of included trials 
Study End Point Randomisation 
Technique 
Concealment Blinding Power Calculation Jadad Score 
Revie et al Length of stay Sealed envelopes Sealed envelope Single Blind Yes 3 
Hughes et al Functional 
recovery 
Sealed envelopes Sealed envelope Open label Yes 4 
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2.4 Discussion  
Debate continues regarding optimal pain management following liver resection. Over the 
years, epidural analgesia has formed the mainstay of pain management over patient-
controlled analgesia (PCA) alone but this has had issues such as inadequate pain relief in 20-
30% of patients 125. Epidurals can make perioperative hemodynamic management more 
complex. There is an increased fluid requirement postoperatively because of epidural induced 
hypotension and this may also require inotropic support 114. In addition, particularly in 
patients undergoing liver resection, there is an increased risk of requiring transfusion 113. In 
the last few years, several RCTs and case-controlled trials compared epidural analgesia and 
wound catheters for analgesia with varying results. The results from this pooled analysis have 
shown that epidural provides better pain management in the first postoperative day with 
comparable pain relief subsequently. The overall complication rate appeared to be higher in 
the epidural group. However, opioid requirements, time to moving bowels and hospital stay 
were comparable between the 2 groups. However, these results need to be interpreted with 
caution given the heterogeneity of the data. 
 
In conclusion, this meta-analysis appears to show that wound catheters provide largely 
comparable pain relief with a lower complication rates and no difference in length of stay 
when compared to epidural catheters. Although some of these studies are well designed 
more data from well-designed studies is required to draw firm conclusions. There are 
significant limitations in this meta-analysis. The studies included vary in the position of the 
wound catheters, postoperative analgesic regimes and even wound incisions. There is, 
however, no current consensus available regarding the optimal site for wound catheters and 
we therefore included all studies. There was no comparable data available to assess 
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complication rates with each catheter technique, failure rate and postoperative fluid 
requirements. Studies involving a small number of patients in this meta-analysis may not have 
had sufficient power to recognize small differences in pain scores and complications 
outcomes between epidural and wound catheter groups. While this meta-analysis does not 
provide data on cost-benefit analysis, results suggest wound catheters provide adequate pain 
relief comparable to epidurals with a lower complication rate.  
 
In general, the quality of some studies investigating the effects of wound catheters following 
liver surgery that are included in this study are poor with only two randomised studies 114, 159, 
both of which were carried out in the same institution. Further randomised studies evaluating 
the impact wound catheters have on perioperative outcomes, including pain scores, 
complications and length of stay, are needed. 
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Justification, Hypothesis and Objectives 
 
Justification 
Good post-operative analgesia is an integral part of ERAS protocols and has the potential to 
improve recovery following surgery. The ideal method of delivering such analgesia would 
provide effective analgesia without side effects. Whilst epidural analgesia can provide good 
analgesia, it is not without unwanted side effects and concern regarding sympathetic 
blockade remains. There are also several alternatives available. Local anaesthetic infiltration 
via abdominal wound catheters in combination with an opioid based PCA is one multi-modal 
approach to analgesia that aims to provide good pain control without the systemic side effects 
associated with thoracic epidurals. The combination of two different modalities also aims to 
minimise opioid use associated with patient-controlled analgesia alone and its accompanying 
side-effects. However, high-quality evidence for their use in patients undergoing liver 
resection is limited with experience from our colleagues in Edinburgh being instrumental. 
There is also very limited evidence evaluating the impact that local anaesthetic infiltration via 
abdominal wound catheters has on the systemic inflammatory response, particularly in 
hepatobiliary surgery. We have designed this study to compare thoracic epidural, the current 
gold standard for postoperative analgesia, with a multimodal regime consisting of local 
anaesthetic infiltration via abdominal wound catheters combined with an opioid based 
patient-controlled analgesia.  
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Hypothesis  
 
We hypothesized that patients receiving thoracic epidural following open liver resection 
would not experience a better recovery to those receiving AWC with PCA and, in fact, 
recovery may be improved with the use of AWC by eliminating the systemic side effects of 
EP. Specifically we hypothesized that: 
  
1. Patients receiving AWC-PCA for post-operative pain relief would not have an inferior 
recovery following open liver resection to those receiving thoracic epidural analgesia, 
which is the current standard of care. 
2.  The use of AWC-PCA for post-operative pain relief following open liver resection 
would not be associated with an increased morbidity when compared to patients 
receiving thoracic epidural analgesia.   
3. The use of AWC-PCA for post-operative pain relief following open liver resection will 
not be associated with an inferior systemic inflammatory response when compared 
to patients receiving thoracic epidural analgesia. 
 
Objectives 
To test our hypotheses, we set the following objectives.  
 
1. To demonstrate that overall recovery was not inferior with the use of AWC-PCA we 
set overall hospital length of stay as the primary endpoint. Additionally, we monitored 
HDU stay and functional recovery as other variables of recovery. 
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2. In order to capture potential morbidity, we measured anaesthetic and surgical times, 
pain scores, peak flow, analgesic requirements, intravenous fluid requirements, 
vasopressor requirements, nausea and sedation scores, complications (stratified 
according to Clavien-Dindo Classification), return to theatre rates and readmission 
rates within 90 days of surgery as well as treatment failure rates. Postoperative 
mortality within 90 days was also recorded. 
 
3. To measure the systemic inflammatory response whole blood samples were collected 
from participants on Day 0, 24- and 72- hours post-operatively. Cytokine levels were 
measured using a cytometric fluid-phase multiplex immunoassay. 
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Chapter 3 
 
 
Clinical Trial 
 
3.1 Methodology 
 
 
The study and ERAS protocols were written and submitted for ethical approval using 
the integrated research application system (IRAS). After some minor amendments this 
RCT was approved by the Yorkshire and Humber Research Ethics Committee and was 
registered with the ISCRCTN registry (16447784). Recruitment commenced in April 
2015 and was completed in November 2017. The study was also approved by the 
Leeds Teaching Hospitals NHS Trust Research and Development Department.  
Patients 
All patients scheduled to undergo open liver resection (OLR), including live liver 
donation, at St James’s University Hospital, Leeds, UK were eligible for inclusion and 
were approached in outpatients by members of the medical or nursing team to discuss 
participation. Patients were provided with written information prior to attendance for 
surgery. Written informed consent was obtained on the morning of surgery. Patients 
were randomized 1:1 after consenting to receive either EP or AWC-PCA according to 
a computer-generated random sequence with concealed allocation. No blinding took 
place as this was not felt to be practical 114. 
Exclusion criteria included patients with a known contraindication to either epidural 
or local anaesthetic, inability to give informed consent, aged less than 18, liver 
resection combined with a second surgical procedure, laparoscopic procedures, 
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pregnant or lactating women, prisoners and patients with a history of chronic pain 
issues requiring regular opioid analgesia.  
 
Perioperative Care 
Patients were fasted for 6 hours prior to surgery and allowed clear fluids up to 2 hours 
before.  
All patients underwent a standard anaesthetic by a team of experienced liver 
resection/transplant anaesthetists. This involved induction of general anaesthesia 
using fentanyl 1-2microgram/kg, sleep dose of propofol and non-depolarising muscle 
relaxant to facilitate endotracheal intubation.  Anaesthesia was maintained with 
mixture of oxygen, air and inhalational agent (sevoflurane, desflurane). Patients were 
monitored with electrocardiogram, pulse oximetry, capnography, arterial blood 
pressure and central venous pressure. Nasogastric tube were not routinely used and 
if used was removed at end of procedure. Maintenance fluid (0.18% sodium 
chloride/4% dextrose) was used to achieve desired central venous pressure. The need 
for intravenous crystalloids was determined by the use of Lidco© in theatre based on 
stroke volume variation. Vasopressors were administered to maintain blood pressure 
within 20% of preoperative range. If patients are hypotensive (systolic blood pressure 
< 20% of preoperative level) despite adequate volume resuscitation then vasopressors 
(noradrenaline as a  single strength solution) would be commenced. Hartmann’s 
solution was used for intraoperative volume replacement after completion of liver 
transection, with vasopressors given at the discretion of the anaesthetist. All patients 
received dexamethasone 8 mg for antiemetic prophylaxis.  
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The type of incision was left to the operating surgeon’s discretion. Parenchymal 
transection was performed using the Cavitron Ultrasonic Surgical Aspirator (CUSA®; 
ValleyLab, Boulder, Colorado, USA). 
 
According to randomisation, epidural catheter or wound catheters plus PCA were 
commenced in theatre according to the study protocol: 
Epidural 
Prior to anaesthetic induction, EP patients received a thoracic epidural at the level of 
T6-10. Epidural infusion was started intraoperatively and consisted of fentanyl (2 
μg/ml) and local anaesthetic (0.15% bupivacaine) at 6-10 ml/hr.  
 
Wound Catheter 
Patients randomized to the AWC-PCA group received an anaesthetic according to the 
same protocol. Prior to abdominal closure, two multi-perforated Painkwell 
(PeakMedical©) catheters were inserted into the transversus abdominis plane 
laterally and the posterior rectus sheath medially. A 20 ml 0.5% bupivacaine bolus (10 
ml per catheter) was followed by an infusion of 0.25% bupivacaine at 4 ml/h per 
catheter for 60 h (POD 3) via an elastomeric pump. Patients in the AWC-PCA group 
also received a morphine based PCA for breakthrough pain with a 5 minute ‘lock-out’.  
Both EP and AWC-PCA provided analgesia for 60 h postoperatively.  
 
Local anaesthetic toxicity can rarely occur with rapid absorption into the blood stream, 
or if inadvertently administered intravenously. Symptoms of local anaesthetic toxicity 
include:  
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1. Mild - restlessness/confusion, light-headedness, numbness of tongue and 
lips, tinnitus, double vision, blurred vision 
  2. Moderate – heaviness of limbs, muscular twitching, convulsions  
3. Severe – cardiac arrhythmias, hypotension, respiratory arrest, cardiac arrest  
  
Recognition and assessment of local anaesthetic toxicity was managed as below:  
1. If symptoms are mild (1);  
1 Stop local anaesthetic infusion and inform medical team  
2 Attach ECG and monitors  
3 Maintain oxygenation and BP  
4 Consult with Pain Team or on call anaesthetist  
5 Continue to observe closely  
2.  If symptoms are moderate or severe (2 or 3):  
   1 Stop local anaesthetic infusion  
   2 Attach ECG and monitors  
3 Phone for help immediately – Bleep ---- medical team / anaesthetist 
or cardiac arrest 2222  
   4 Maintain airway and give high flow oxygen.  
5 Hypotension will be treated with IV fluids 
6 Convulsions will be treated with diazepam  
7 Commence CPR if in cardiac arrest  
 
Emergency Treatment of Local Anaesthetic Toxicity 
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1 Collect Lipid Rescue Box from the nearest recovery area or operating 
theatre if patient is in local anaesthetic induced cardiac arrest.  
2 Treatment will require intravenous Intralipid 20% (from the lipid rescue 
box). The initial dose is 1.5ml/kg over 1 minute, followed by an intravenous 
infusion of 15ml/kg over 1 hour.  
3 For a 70kg adult this means 100mls over 1 minute followed by 1000mls 
over 1 hour.  
4 Refer to The Association of Anaesthetists of Great Britain and Ireland safety 
guideline ‘Management of Severe Local Anaesthetic Toxicity’.  
Perioperatively, patients were managed according to an ERAS Protocol. Patients were 
warmed pre- and intra-operatively with 3M™Bair Hugger™ Normothermia system. 
Patients were given high carbohydrate drinks preoperatively except in patients with a 
past medical history of diabetes. Patients received perioperative intravenous 
antibiotics prior to skin incision and routine venous thromboprophylaxis. Nasogastric 
tube and intraperitoneal drains were used at the surgeon’s discretion. Epidural failure 
was managed with conversion to PCA. Treatment failure was judged by the acute pain 
team independent from the study. It was defined as accidental dislodgment of the 
EP/AWC requiring removal or significant pain scores needing PCA. These patients were 
kept in the trial for the purposes of the intention to treat analysis. 
 
Postoperative 
Patients were transferred from the theatre complex to the surgical high-dependency 
unit (HDU) where they remained until discharge to ward criteria were met. These 
included: 
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- Respiratory 
o Requiring less than 40% Oxygen 
o Respiratory rate <20 >10 
o SpO2 >94% 
- Cardiovascular 
o No CVP/invasive BP monitoring required 
o ECG monitoring not required 
o No vasopressor requirements or large boluses of fluid 
- Renal 
o Stable renal function on biochemistry 
o Urine output >25ml/hr 
- Analgesia 
o Pain control adequate with current method of analgesia 
- Blood tests 
o Improving  
- General 
o Able to mobilise out of bed 
 
 A standard oral analgesic scheme was followed for all patients from the first 
postoperative day. This included paracetamol (1gm four times daily), ibuprofen 
(400mg three times daily for 72 hours) and codeine (30-60 mg/qds) or tramadol 
(100mg four times daily) once the PCA had been discontinued. Ondansetron (4 mg 
three times daily) was used as antiemetic prophylaxis. All patients who are euvolaemic 
and haemodynamically stable will be encouraged to return to oral fluid administration 
as soon as possible. 
Similarly, patients remained on the ward until discharge home criteria were fulfilled. 
These included: 
- Adequate pain control on oral analgesia.  
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- Eating and drinking with no requirement for intravenous fluids in previous 24 
hours.  
- Independently mobile (can mobilise independently to toilet).  
- Able to perform activities of daily living (washing, dressing) without help from 
nursing staff.  
- Blood tests returning to normal range.  
- Patient willing to go home. 
 
 
Outcomes 
To investigate the hypothesis the following outcome measures were defined: 
Length of Stay 
The primary outcome was the length of stay (from admission to discharge), which was 
assessed twice daily by a senior clinician independent from the study. In addition, days 
to meet ‘medically fit for discharge’ criteria functional recovery and length of high 
dependency (HDU) stay were also recorded. 
 
Assessment of Pain 
Pain scores at rest on a scale from 0 to 10 at 6 h postoperatively (Day 0) and then twice 
a day at 08:00-09:00 and 16:00-17:00. Scores were recorded by nursing staff 
independent of the study. PCA use, including attempted use, was recorded in addition 
to oral analgesia requirements and were converted to intravenous opiate equivalent.  
 
Other Outcomes 
Nausea and sedation scores were recorded at the same time points as pain scores. 
Peak flow measurements (best of 3) as a surrogate of pain were recorded pre-
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operatively and twice a day for the first 3 days. Total volumes of intravenous fluid and 
the need for vasopressor support postoperatively were also monitored daily as were 
time to open bowels and time to sit out of bed. 
 
Complications 
Patients were monitored for complications routinely during their recovery. 
Complications were graded according to the Clavien-Dindo classification 205.  
 
Statistical Analysis 
A sample size calculation based on a mean historical length of stay of 9.8 days (SD 
8.2)(median 7) with a clinically significant difference of one day. To achieve a 
significance of 0.05 and 80% power, 40 patients per arm were required. Given the 
nature of the study very few patients were expected to drop-out or be lost to follow 
up. Continuous data was compared using the Mann-Whitney U test and categorical 
data was compared using χ2. Analysis was performed on an intention to treat basis. 
SPSS® Version 25 was used for statistical analysis.  
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3.2 Results 
 
 
The trial commenced in April 2015 and was completed in November 2017. A total of 153 
patients were approached to participate. A CONSORT flow diagram is shown in Figure 7. No 
patients were lost to follow up. Among the patients approached 83 patients were eligible and 
consented to participation. These were randomly allocated to either epidural (n=41) or 
abdominal wound catheters groups (n=42).  
 
Patient Characteristics 
Patients in both groups were comparable with regards to age, sex, body mass index, baseline 
peakflow and American Society of Anaesthesiologists (ASA) grade. Indications for surgery 
were colorectal liver metastases (CRLM, 50, 60%), hepatocellular carcinoma (HCC, 12, 14%), 
cholangiocarcinoma (CCA, 8, 10%), benign disease (9, 11%) and other causes (4, 5%). There 
were no significant differences between the two groups with regards to baseline 
characteristics. Operatively, the proportion of patients requiring a ‘major’ liver resection was 
comparable as were the median number of segments resected. There was no difference 
between the two groups regarding wound shape or length. Patient characteristics are shown 
in Table 4. 
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Table 4: Baseline Characteristics 
 
 EP 
(n=41) 
% or Range AWC 
(n=42) 
% or Range P Value 
Age, median (year) 67.3 25-85 65 24-79 0.133 
Sex (Female) 12 29% 15 36% 0.348 
ASA II 16 39% 17 40% 0.830 
BMI (median, kg/m2) 26 18-41 28 23-42 0.115 
Baseline Peakflow 
Median (L/min) 
395 (170-700) 415 (210-800) 0.379 
Diagnosis 
CRLM 
HCC 
CCA 
Benign 
Other 
 
27 
5 
5 
3 
1 
 
66% 
12% 
12% 
7% 
3% 
 
23 
7 
3 
6 
3 
 
55% 
17% 
7% 
14% 
7% 
 
 
0.534 
PVE 2 5% 2 5% 0.683 
Major Resection 23 56% 24 57% 0.574 
Anatomical resection 21 51% 23 55% 0.298 
Number of Segments 
(median) 
4 (0-6) 3 (0-5) 0.291 
Wound Shape 
Reverse ’J’ 
Kocher 
Midline 
 
36 
1 
4 
 
88% 
2% 
10% 
 
36 
1 
5 
 
86% 
2% 
12% 
 
0.559 
Wound Length 
(median, cm) 
28 17-45 27.5 15-36 0.458 
Prior Abdo. Surgery 27 66% 23 55% 0.302 
Redo Liver Resection 6 14% 3 7% 0.272 
Intraop. Transfusion 2 5% 0 0% 0.147 
ASA - American Society of Anaesthesiology, BMI - Body Mass Index, CRLM – colorectal liver 
metastases, HCC – hepatocellular carcinoma, CCA – cholangiocarcinoma, PVE – portal vein 
embolisation 
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Primary End Point: Length of stay 
The overall length of stay (median) was comparable between the two groups (EP 6 days (3-
27) vs 6 days (3-66), p=0.886).  The median number of days to meet ‘medically fit for 
discharge’ criteria between the two groups was also comparable (EP, 5 days (3-27) vs. AWC 5 
days (3-66), p=0.611).). The median length of stay on HDU between the two groups was 
comparable (EP 1 day (1-6) vs. AWC 1 day (0-6), p=0.097).  
 
Perioperative Outcomes 
The median anaesthetic time in the AWC group was shorter (AWC 49 min (20-115) vs. EP 62 
min (20-126), p=0.003) but there was no significant difference in median surgical time (AWC 
203 min (90-402) vs. EP 170 min (80-390), p=0.095) despite the potential complexity of 
inserting the AWC at the end of the procedure. The volume of intra-operative fluid and the 
proportion of patients requiring HDU admission post-surgery. Intraoperatively patients in the 
AWC group were more likely to require metaraminol boluses to maintain blood pressure 
whereas the EP group required noradrenaline infusion (p=0.01). See Table 5. 
 
Postoperative Outcomes 
Patients randomised to the EP group required significantly more vasopressor support on day 
0 (AWC 14% vs. EP 54%, p = <0.001) and day 1 (AWC 5% vs. EP 23%, p=0.021). Intravenous 
fluid requirements were comparable until post-operative day 3 when approximately one-
third of patients in the EP group required IV fluid (p=0.001). Median pain scores were worse 
on day 0, afternoon of day 1 and the morning of day 2 in the AWC group but not beyond this. 
Median pain scores in both groups at all time points were <3 and were thus considered to be 
low. See Table 5 and Figure 8. 
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No difference was noted in baseline peak flow between the two groups. However, reduction 
in peak flow from baseline was greater in the AWC group up to Day 3. Opioid requirements 
(IV morphine equivalent, mg) were greater in the AWC group on Day 0, Day 1 and Day 2. See 
Table 7. 
 
Other Outcomes 
In the EP group, 8 (20%) patients experienced treatment failure versus 3 (7%) patients in the 
AWC group (p=0.09). No differences were noted in nausea or sedation scores at any time 
point throughout the study. The number of days to open bowels was also comparable, both 
median 3 days (p=0.145) as was the time to first sit out (p=0.563).  Complication rates were 
comparable between the EP and AWC groups being 29% vs 31% respectively (p=0.867). 
Similarly, no difference was noted in severe complications (Clavien-Dindo >3). Perioperative 
mortality was 2% in each group (p=0.747). See Table 5. 
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Figure 7: CONSORT Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Baseline Characteristics 
 
 
 
Assessed for eligibility (n=153) 
Excluded  (n=69) 
   Not meeting inclusion criteria (n=0) 
   Declined to participate (n=66) 
   Other reasons (n=3) 
 Required heparin - no epidural n=1 
 Refused epidural n=2 
Analysed (intention to treat) (n=41) 
 Excluded from analysis (n=0) 
Lost to follow-up (n=0) 
Patient Death (n=1) 
 
Allocated to Epidural (n=42) 
 Received allocated intervention (n=41) 
− Unable to insert epidural (n=1) - excluded 
Lost to follow-up (n=0) 
Patient Death (n=1) 
Allocated to AWC-PCA (n=42) 
 Received allocated intervention (n=42) 
 Did not receive allocated intervention (n=0) 
Analysed (Intention to treat) (n=42) 
 Excluded from analysis (n=0) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=84) 
Enrolment 
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Figure 8: Pain Scores 
 
0
1
2
3
4
5
6
7
8
9
10
Day 0 p=0.023 Day 1 am -
p=0.238
Day 1 pm
p=0.040
Day 2 am
p=0.046
Day 2 pm
p=0.749
Day 3 am
p=0.106
Day 3 pm
p=0.313
Day 4 am
p=0.956
Day 4 pm
p=0.482
Day 5 am
p=0.190
Day 5 pm
p=0.157
Day 6 am
p=0.815
Day 6 pm
p=0.915
Visual Analogue Pain Scores
AWC Epi
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Table 5: Peri- and Post-Operative Outcomes 
 EP 
(n=41) 
% or Range AWC 
(n=42) 
% or Range P Value 
Anaesthetic Time (min) 
(median, range) 
(mean, SD) 
 
62 
64 
 
20-126 
23 
 
49 
50 
 
20-115 
19 
 
0.003 
 
Surgical Time (min) 
(median, range) 
(mean, SD) 
 
170 
187 
 
80-390 
75 
 
203 
212 
 
90-402 
81 
 
0.095 
Intraoperative Opioid 
(IV Morphine Equivalent, mg) 
 
15 
 
3-30 
 
13.5 
 
0-45 
 
0.548 
Intraoperative Vasopressors 
None 
Noradrenaline Infusion 
Metaraminol 
 
13 
23 
5 
 
32% 
56% 
12% 
 
19 
10 
13 
 
45% 
24% 
31% 
 
 
0.001 
 
Intraoperative fluid (ml) 
(median, range) 
(mean, SD) 
 
2000 
2267 
 
1000-6000 
1178 
 
2000 
2262 
 
1000-6000 
989 
 
0.579 
HDU Admission 38 93% 39 93% 0.644 
Requirement for Vasopressors 
Day 0 22 54% 6 14% <0.001 
Day 1 9 22% 2 5% 0.021 
Day 2 3 7% 1 2% 0.305 
Intravenous Fluid Requirement (ml) 
Day 0 (median, range) 
(Mean, SD) 
1650 
1675 
600-3826 
742 
1663 
1890 
664-3596 
740 
 
0.282 
No. requiring IVI 41/41 100% 42/42 100% 
Day 1 (median, range) 
(Mean, SD) 
1550 
1787 
100-4650 
1057 
1437 
1503 
250-4667 
915 
 
0.294 
No. requiring IVI 41/41 100% 42/42 100% 
Day 2 (median, range) 
(Mean, SD) 
490 
890 
0-4639 
1094 
80 
623 
0-3246 
883 
 
0.177 
No. requiring IVI 27/41 66% 22/42 52% 
Day 3 (median, range) 
(Mean, SD) 
0 
552 
0-3000 
866 
0 
65 
0-2000 
359 
 
0.001 
No. requiring IVI 13/41 32% 1/42 2% 
Peak Flow from baseline (L/min) 
Day 0 80 -10-450 160 10-260 0.015 
Day 1 am 150 -30-580 170 0-500 0.012 
Day 1 pm 100 -60-500 180 0-400 0.005 
Day 2 am 120 -10-350 215 0-500 0.001 
Day 2 pm 110 -60-590 180 0-450 0.039 
Day 3 am 100 -20-610 180 0-450 0.033 
Day 3 pm 110 -60-590 145 0-300 0.291 
Other Variables 
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Days to Bowels Open (days) 
(median, range) 
(mean, SD) 
 
3 
3 
 
1-7 
1.4 
 
3 
3.5 
 
0-8 
1.6 
 
0.145 
Time to sit out (hr) 
(median, range) 
(mean, SD) 
 
17 
17.3 
 
15-26 
1.4 
 
16.5 
16.7 
 
4-20 
3.2 
 
0.563 
Length of Stay HDU (days) 
(median, range) 
(mean, SD) 
 
1 
1.8 
 
1-6 
1.4 
 
1 
1.3 
 
0-6 
1 
 
0.097 
MFFD (days)  
(median, range) 
(mean, SD) 
 
5 
6.8 
 
3-27 
4.8 
 
5 
8.2 
 
3-66 
11 
 
0.611 
Length of Stay (days) 
(median, range) 
(mean, SD) 
 
6 
7.2 
 
3-38 
6 
 
6 
8.7 
 
3-66 
11.7 
 
0.886 
Complications 12 29% 13 31% 0.867 
Clavien-Dindo 
I 
II 
IIIa 
IIIb 
Iva 
Ivb 
V 
 
2 
4 
2 
2 
1 
0 
1 
 
5% 
10% 
5% 
5% 
2% 
0% 
2% 
 
2 
4 
0 
1 
3 
2 
1 
 
5% 
10% 
0% 
2% 
7% 
5% 
2% 
 
 
 
0.506 
Treatment Failure  8 20% 3 7% 0.07 
Re-Operation 3 7% 3 7% 0.500 
90-Day Readmission 2 5% 7 16% 0.077 
90-Day Mortality 1 2% 1 2% 0.747 
IV – Intravenous, HDU – High Dependency Unit, MFFD – medically fit for discharge 
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Table 6: Visual Analogue Pain Scores at all Time Points 
 
 Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 
am pm am pm am pm am pm am pm am pm 
EP (n=41) 
(median, 
range) 
(mean, SD) 
 
1 (0-8) 
1.6 
(2.1) 
 
2 (0-9) 
2.7 
(2.4) 
 
 
1 (0-8) 
2 (2.1) 
 
2 (0-8) 
2.6 
(2.5) 
 
2 (0-10) 
2.5 
(2.7) 
 
2 (0-9) 
2.5 (2) 
 
2 (0-8) 
2.6 
(2.3) 
 
2 (0-9) 
3 (2.0) 
 
2 (0-9) 
2.5 
(2.1) 
 
2 (0-8) 
2.8 
(2.4) 
 
2 (0-6) 
2.1 
(1.9) 
 
2.5 (1-
6) 
3.1 
(1.8) 
 
3 (0-6) 
3 (1.9) 
AWC (n=42) 
(median, 
range) 
(mean, SD) 
 
3 (0-6) 
2.3 
(1.8) 
 
2 (0-8) 
3.1 
(2.2) 
 
2.5 (0-
8) 
3.0 
(2.4) 
 
3 (1-10) 
3.4 
(2.4) 
 
2 (0-8) 
2.4 
(2.0) 
 
3 (0-8) 
3.2 
(2.2) 
 
3 (0-7) 
3.0 
(2.1) 
 
2 (0-8) 
3.2 
(2.6) 
 
2 (1-8) 
3.2 
(2.3) 
 
3 (1-8) 
3.6 
(2.1) 
 
3 (0-10) 
3.6 
(2.9) 
 
2 (0-10) 
3.2 
(2.4) 
 
3 (0-10) 
3.6 
(3.6) 
P Value 0.023 0.238 0.040 0.046 0.749 0.106 0.313 0.956 0.482 0.190 0.157 0.815 0.915 
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Table 7: Total Analgesic Requirements (IV Morphine Equivalent, mg) 
 Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 
AWC-PCA (n=42) 
Median (Range) 
Mean (SD) 
 
18.5 (0-76) 
20 (16) 
 
14 (0-81) 
21 (22) 
 
2 (0-129) 
11 (25) 
 
1 (0-10) 
1 (1.9) 
 
0.25 (0-5) 
1.1 (1.4) 
 
0 (0-5) 
1 (1.5) 
EP (n=41) 
Median (Range) 
Mean (SD) 
 
0 (0-70) 
3 (13) 
 
0 (0-89) 
10 (22) 
 
0 (0-128) 
8.7 (24) 
 
2 (0-80) 
7 (16) 
 
1 (0-96) 
4 (15) 
 
0 (0-8) 
1 (1.5) 
EP Failure (n=8) 
Median (Range) 
Mean (SD) 
 
2 (0-70) 
19 (28) 
 
43 (12-89) 
46 (30) 
 
16 (1-128) 
33 (44) 
 
0.5 (0-80) 
5 (12) 
 
1 (0-2) 
1 (1.1) 
 
0.25 (0-2) 
1 (1) 
P Value <0.001 <0.001 <0.001 0.004 0.455 0.712 
Kruskal-Wallis on median, EP Failure was managed with PCA alone 
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Chapter 4 
 
Analysis of Systemic Inflammatory Response 
4.1 Methodology 
Analysis of the Systemic Inflammatory Response 
A substantial ethical amendment was submitted to the Yorkshire and Humber Research Ethics 
Committee to approve the systemic inflammatory response analysis work in April 2016. This 
was approved in June 2016 and, following local R&D approval, sample collection began in 
August 2016. Patients from the first half of the study were therefore not included in the 
systemic inflammatory response analysis work and therefore the subsequent 30 patients 
were recruited. Whole blood was collected in an EDTA tube using a standard technique from 
participants in the second half of the RCT. Samples were collected at Day 0 (day of surgery), 
24 and 72 h post-operatively. Samples were transferred to the laboratory on ice before being 
centrifuged (4C at 900g for 10 minutes). The separated plasma was then stored at -80°C after 
being divided into 0.5ml aliquots. Cytokine levels were measured using Bio-Plex Pro ™ 
(Human Cytokine 27-plex Assay, Bio-Rad Laboratories, Hemel Hempstead, UK) in a batch 
analysis once all samples had been obtained. Cytokines analysed for were IL-1, IL-1ra, IL-2, 
IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, eotaxin, basic FGF, G-CSF, GM-
CSF, IFN-, IP-10, MCP-1, MIP-1, MIP-1, PDGF-BB, RANTES, TNF- and VEGF. 
Initial preparation for the cytokine analysis involved bringing the assay buffer, wash buffer 
and sample diluent to room temperature and thawing the samples. Thawed samples were 
diluted at a ratio of 4:1 with Bio-Plex sample diluent HB. The wash station was primed and 
wash buffer prepared and diluted 1-part 10x wash buffer (60ml) with 9 parts dH20 (540ml). 
The Bio-Plex system was then calibrated. A single vial of standards was reconstituted in 500l 
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of standard diluent HB and then vortexed for 5 seconds before incubating on ice for 30 
minutes. A fourfold standard dilution series was prepared with 5 seconds of vortex between 
liquid transfers. The coupled beads were then vortexed for 30 seconds and diluted in Bio-Plex 
Assay Buffer. This was then protected from light. The diluted beads were then vortexed for 
10-20 seconds before adding 50l to each well of the assay plate. The plate was then washed 
twice with 100l Bio-Plex Wash Buffer. Samples were then vortexed and 50l added to each 
well. The plate was then covered with sealing tape and incubated on a shaker at 850 rpm at 
room temperature for 30 minutes.  
With 10 minutes remaining in the incubation, the detection antibodies were vortexed for 5 
seconds, quick spun and liquid collected before diluting to 1x concentration (300l detection 
antibody:2700l detection antibody diluent HB). The plate was washed with three times with 
100l of buffer, the diluted detection antibodies vortexed and 25l added to each well. The 
plate was then covered and incubated on the shaker at 850rpm for 30 minutes at room 
temperature. The standard S1 values from the assay kit were entered into the Bio-Plex 
manager Software. With approximately 10 minutes left in the incubation process, the 100x 
streptavidin-phycoerythrin (SA-PE) was vortexed for 5 seconds, quick spun and the fluid 
collected. This was diluted to 1x by mixing 60l SA-PE with 5940l of assay buffer. The plate 
was washed three times with 100l wash buffer and 50l of vortexed diluted SA-PE added to 
each well. The plate was again covered, shaken at 850rpm for 10 minutes at room 
temperature. The plate was then washed three times with 100l of wash buffer. The beads 
were resuspended in 125l assay buffer, the plate covered and shaken at 850 rpm for 30 
seconds. The plate was then read using low PMT, RP1 settings for the Bio-Plex 3D System (Bio-
Rad Laboratories, Luminex Corporation).  
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The effect of time and analgesic modality on cytokine response was analysed using two-way 
ANOVA with repeated measures after testing for normal distribution using SPSS version 25.
  70 
4.2 Results 
Thirty patients were recruited into the cytokine analysis. There were more patients in the 
AWC group (n=17) than the EP group (n=13). Patients in the EP group were more likely to be 
ASA II and have a larger portion of liver resected. The AWC-PCA group had a significantly 
shorter anaesthetic time and longer surgical time. There was a non-significant trend towards 
more serious complications (Clavien-Dindo grade 3) in the AWC-PCA group, 4/8 
complications versus 0/4 complications in the EP group. The demographics for patients 
enrolled in the cytokine analysis are available in Table 8. 
 
The level of IL-9 and MIP-1 were significantly lower over time in the AWC-PCA group. Levels 
of these two cytokines fell from baseline levels at the two other timepoints in the AWC-PCA 
group whereas levels in the EP group rose. There were no other significant differences with 
regards to the systemic inflammatory response when taking into account time and analgesic 
modality. These results are summarised in Table 9 and Figure 9. 
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Table 8: Demographics For Patients in Cytokine Analysis 
 
 
 
*comparison of serious complications (Clavien-Dindo 3) 
 
 EP (range/%) 
(n=13) 
AWC (Range/%) 
(n=17) 
P Value 
Age, median (year) 
(Mean (SD)) 
63 (57-81) 
66 (8) 
58 (42-75) 
61 (10) 
0.116 
Sex (Female) 5 (38%) 5 (29%) 0.602 
ASA II 11 (85%) 6 (35%) 0.005 
BMI (median, kg/m2) 26 (22-37) 
27 (5) 
27 (25-35) 
29 (4) 
0.537 
Baseline Peakflow 
Median (L/min) 
390 (240-500) 
387 (93) 
400 (250-640) 
455 (127) 
0.198 
Diagnosis 
CRLM 
HCC 
CCA 
Benign 
Other 
 
8 
3 
2 
0 
0 
 
10 
0 
4 
2 
1 
 
 
0.167 
Major Resection 9 (69%) 7 (41%) 0.127 
Anatomical resection 9 (69%) 9 (53%) 0.611 
Number of Segments 
 
4 (2-6) 
4 (1) 
2 (1-4) 
2 (1) 
0.03 
Wound Shape 
Reverse ’L’ 
Kocher 
Midline 
 
10 (77%) 
1 (8%) 
2 (15%) 
 
14 (82%) 
2 (12%) 
1 (6%) 
 
0.587 
Wound Length (cm) 29 (17-34) 
27 (5) 
27 (16-32) 
27 (4) 
0.251 
Prior Abdo. Surgery 6 9 0.713 
Redo Liver Resection 1 3 0.427 
Anaesthetic Time 
(min) 
60 (41-126) 
71 (25) 
41 (20-115) 
45 (22) 
0.002 
Surgical Time 180 (110-330) 
180 (63) 
213 (100-375) 
254 (94) 
0.036 
Complications 4 (31%) 8 (53%) 0.367 
Clavien-Dindo 
I 
II 
III 
IV 
V 
 
0 
4 
0 
0 
0 
 
1 
3 
0 
3 
1 
 
 
0.083* 
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Table 9: Assessment of the systemic inflammatory response between Abdominal Wound 
Catheters + PCA versus Thoracic Epidural following Open Liver Resection  
 
 
 Day 0 
(pg/ml) 
Day 1 
(pg/ml) 
Day 3 
(pg/ml) 
P value* 
 
IL-1 
AWC-PCA 0.03 (0-1.03) 
0.18 (0.29) 
0 (0-1.17) 
0.08 (0.28) 
0 (0-0.76) 
0.07 (0.22) 
 
0.336 
EP 0 (0-0.76) 
0.22 (0.29) 
0 (0-1) 
0.10 (0.27) 
0.03 (0-637) 
65 (191) 
 
IL-1ra 
AWC-PCA 73 (47-485) 
146 (132) 
98 (40-344) 
120 (78) 
119 (44-288) 
149 (80) 
 
0.287 
EP 52 (34-101) 
63 (23) 
71 (23-740) 
130 (192) 
78 (31-637) 
169 (198) 
 
IL-2 
AWC-PCA 3.2 (1.1-4.3) 
3.2 (1.1) 
2.7 (0.1-7.1) 
2.6 (1.6) 
2.3 (0.1-5.7) 
2.4 (1.7) 
 
0.051 
EP 3.2 (0.1-1) 
3.3 (2.4) 
2.7 (0.1-4.9) 
2.4 (1.4) 
3.2 (0-4.3) 
2.9 (1.4) 
 
IL-4 
AWC-PCA 1.1 (0.3-1.5) 
1 (0.38) 
0.88 (0.2-3.4) 
0.97 (0.77) 
0.69 (0.3-3.2) 
1 (0.86) 
 
0.564 
EP 0.9 (0.3-3.2) 
3.2 (1.1) 
0.7 (0.2-1.3) 
0.79 (0.4) 
1.1 (0.4-2.3) 
1.2 (0.6) 
 
IL-5 
AWC-PCA 7.2 (2.3-15.2) 
7.3 (3) 
5.9 (1.2-15.1) 
6.2 (3.6) 
4.7 (0.3-16.5) 
5.8 (4.5) 
 
0.064 
EP 7.2 (1.2-35.6) 
8.7 (8.5) 
3.5 (0.7-16.5) 
5.9 (4.5) 
8.5 (0-12.4) 
8.4 (3.7) 
 
IL-6 
AWC-PCA 3.6 (1.4-8.8) 
3.7 (2.1) 
6.5 (1-13.4) 
6.2 (3.7) 
5.3 (1-9.4) 
4.4 (3) 
 
0.830 
EP 2.5 (0.5-6.6) 
2.2 (1.6) 
5.8 (0.5-31.1) 
2 (8.5) 
7.7 (0.9-27) 
3.6 (9) 
 
IL-7 
AWC-PCA 10 (0-48.3) 
14.4 (13.2) 
6.2 (0-102.2) 
15.2 (24.7) 
6.2 (0-94.5) 
17.5 (28.1) 
 
0.341 
EP 13.8 (0-59.8) 
15.7 (16.7) 
0 (0-48.3) 
8.7 (13.8) 
6.2 (0-40.6) 
15.4 (16.6) 
 
IL-8 
AWC-PCA 6.4 (2.1-16) 
6.9 (3.7) 
9.2 (3.7-23.6) 
10.6 (6) 
11.7 (1.6-21) 
12.2 (6.7) 
 
0.445 
EP 3.7 (1.1-27.5) 
6.5 (7.4) 
7 (1.6-53.6) 
12.3 (14.5) 
9.9 (1.6-46.5) 
16 (14.8) 
 
IL-9 
AWC-PCA 99 (61-119) 
94 (18.5) 
80.5 (46-123) 
84 (22.9) 
82.9 (54-142) 
85.3 (25.4) 
 
0.005 
EP 79.7 (70-116) 
90 (18) 
78 (49-121) 
83 (22) 
95 (67-133) 
101 (24) 
 
IL-10 
AWC-PCA 1.7 (0-49) 
6.2 (13) 
2.8 (0-8.1) 
3.1 (2.6) 
1.2 (0-5.4) 
1.9 (2) 
 
0.255 
EP 0.4 (0-5.7) 
1 (1.6) 
0.8 (0-5.4) 
1.5 (1.7) 
2.1 (0-6.1) 
2.1 (2.3) 
 
IL-12 
AWC-PCA 0.82 (0-2.9) 
0.95 (0.9) 
0 (0-5.6) 
0.8 (1.5) 
0 (0-2.9) 
0.5 (1.0) 
 
0.857 
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EP 0.4 (0-17) 
1.4 (3.1) 
0 (0-5.6) 
0.8 (1.4) 
0 (0-2.9) 
0.6 (0.9) 
 
IL-13 
AWC-PCA 1.2 (0.9-2) 
1.3 (0.3) 
1.0 (0.7-2.5) 
1.1 (0.4) 
0.9 (0.7-2.3) 
1.1 (0.4) 
 
0.060 
EP 1.3 (0.8-1.5) 
1.2 (0.3) 
1.2 (1-1.2) 
1.1 (0.1) 
1.2 (1.2-1.7) 
1.3 (0.3) 
 
IL-15 
AWC-PCA 0 (0-0) 
0(0) 
0 (0-0) 
0 (0) 
0 (0-0) 
0 (0) 
 
0.999 
EP 0 (0-52) 
4 (14.5) 
0 (0-0) 
0 (0) 
0 (0-0) 
0 (0) 
 
IL-17 
AWC-PCA 7.3 (5-10.6) 
7.3 (1.4) 
6.3 (3.2-10.6) 
6.3 (2.1) 
5.3 (3.2-12.1) 
6 (2.6) 
 
0.367 
EP 6.9 (5-12) 
7.5 (2.3) 
6.3 (3.8-9.8) 
6.3 (1.6) 
6.4 (3.8-9.1) 
6.6 (1.6) 
 
Eotaxin 
AWC-PCA 9.0 (4.4-26.2) 
10.1 (5.0) 
7.0 (2.3-18.2) 
7.3 (3.8) 
5.3 (2.4-9.8) 
5.6 (2.8) 
 
0.407 
EP 10.3 (5.5-17.8) 
10.7 (4.0) 
7.3 (2.4-24.5) 
9.9 (7.2) 
7.1 (3.1-23.6) 
9.1 (6.3) 
 
FGF Basic 
AWC-PCA 10.8 (3.6-21.3) 
10.9 (4.6) 
6.3 (0-21.3) 
6 (6) 
0 (0-18.1) 
5 (7.1) 
 
0.317 
EP 10.8 (0-24.4) 
10.5 (7.3) 
6.3 (0-14.6) 
6.2 (5.1) 
8.6 (0-18.1) 
9.3 (7.3) 
 
G-CSF 
AWC-PCA 24.3 (8.9-61.1) 
29.6 (17.2 
40.4 (14-136) 
50.8 (32.2) 
32.9 (7-142) 
56.6 (48.7) 
 
0.397 
EP 22.7 (4.8-85.8) 
30.2 (23.8) 
29.3 (11-86) 
39.9 (26.2) 
46.6 (7-102) 
48.4 (32.3) 
 
GM-CSF 
AWC-PCA 0.1 (0-0.9) 
0.2 (0.3) 
0 (0-0.8) 
0.1 (0.2) 
0 (0-0.8) 
0.1 (0.3) 
 
0.790 
EP 0.2 (0-3.8) 
0.5 (1) 
0 (0-0.9) 
0.2 (0.3) 
0.3 (0-0.9) 
0.4 (0.3) 
 
IFN- 
AWC-PCA 5.3 (1.1-12) 
5.3 (2.7) 
3.8 (0.3-12.9) 
4.6 (3) 
3.4 (0.6-14.7) 
4.8 (5.3) 
 
0.150 
EP 4.5 (1.1-19.5) 
5.8 (4.7) 
3.8 (0.6-9.4) 
4.1 (2.7) 
5.3 (0.6-8.1) 
5.3 (2.4) 
 
IP-10 
AWC-PCA 82 (46-190) 
87 (38) 
52 (24-120) 
57 (22) 
50 (40-78) 
53 (12) 
 
0.118 
EP 96 (48-1034) 
168 (263) 
56 (24-1185) 
145 (313) 
67 (50-149) 
82 (35) 
 
MCP-1 
AWC-PCA 17.7 (4.8-113) 
28.4 (29.5) 
25.9 (7.3-88) 
31.1 (20.5) 
21 (8.7-36) 
23.4 (9.4) 
 
0.147 
EP 17.4 (5.5-54) 
19.3 (13.5) 
17 (3-80) 
24.7 (25.3) 
17 (4-84) 
28 (25) 
 
MIP-1 
AWC-PCA 0.7 (0.3-2) 
0.8 (0.4) 
0.6 (0-2.3) 
0.8 (0.6) 
0.6 (0.2-2.3) 
0.9 (0.7) 
 
0.109 
EP 0.8 (0.2-2.3) 
0.8 (0.5) 
0.6 (0-2) 
0.8 (0.5) 
0.9 (0.1-2) 
1 (0.6) 
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PDGF-bb 
AWC-PCA 357 (152-2406) 
588 (604) 
100 (0-1093) 
213 (288) 
44 (4-547) 
139 (167) 
 
0.933 
EP 428 (94-1008) 
449 (320) 
237 (44-1638) 
375 (424) 
242 (0-942) 
333 (293) 
 
MIP-1 
AWC-PCA 50 (32-74) 
50 (12) 
47 (24-66) 
46 (12) 
41 (28-61) 
42 (11) 
 
0.002 
EP 48 (33-65) 
47 (10) 
51 (30-65) 
49 (11) 
52 (32-74) 
53 (13) 
 
TNF- 
AWC-PCA 22 (12-37) 
22 (7) 
20 (7-46) 
21 (11) 
18 (9-48) 
23 (12) 
 
0.385 
EP 20 (10-44) 
22 (8) 
20 (7-31) 
19 (7) 
22 (10-35) 
24 (8) 
 
VEG-F 
AWC-PCA 0.5 (0-90) 
18 (27) 
0.5 (0-66) 
11 (19) 
0 (0-61) 
9 (18) 
 
0.741 
EP 25 (0-86) 
26 (25) 
0 (0-45) 
9 (16) 
17 (0-49) 
18 (18) 
Comparison using 2-Way ANOVA with repeated measures.  
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Figure 9: Graphs Comparing Systemic Inflammatory Response between Abdominal Wound 
Catheters and Thoracic Epidural 
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Chapter 5 
 
 
Discussion 
 
5.1 Discussion 
 
This RCT aimed to compare outcomes after OLR depending on whether EP or AWC-PCA was 
used within a program of ERAS. Up to commencing this trial EP has been the standard of care 
in our institution. At the outset of this study only one RCT had been reported comparing AWC 
with EP following OLR noting a shorter functional recovery but inferior pain control in the first 
48 hours 114. A second study from the same group was published during our study also 
showing faster functional recovery but with comparable pain relief 159. We assumed that the 
use of AWC-PCA would avoid the sympathetic blockade associated with EP thus leading to 
reduced intravenous fluid infusion, reduced vasopressor support, reduced HDU stay and 
ultimately faster recovery. Thus, a cohort of 83 patients was recruited and randomized 
preoperatively and given the nature of the study, no differences in baseline demographics 
were seen.  
This randomised controlled trial has demonstrated that thoracic epidural was not superior to 
AWC-PCA with regards to length of stay following open liver resection. The use of thoracic 
epidural following open liver resection was associated with a significantly greater need for 
vasopressor support up to two days postoperatively than with a multimodal analgesic 
regimen of local anaesthetic infiltration via abdominal wound catheters in combination with 
patient-controlled analgesia. As expected for this study design the baseline patient 
demographics were comparable between the two groups as were the operative factors.  
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Other findings included a shorter anaesthetic time with AWC-PCA and comparable 
intravenous fluid requirements, return of bowel function and time to mobilise. In addition, it 
has also shown that pain control associated with AWC-PCA was worse at all time points up to 
the morning of postoperative day 2, with the exception of the morning of postoperative day 
1 but was comparable thereafter. However, pain scores in both groups were regarded as low 
at all time points in both groups. This is also demonstrated in the peak flow results taken at 
the same time points. These differences did not translate into a shorter HDU stay or shorter 
functional recovery. The rate of complications, severity of complications and 90-day mortality 
rates were comparable. No differences were seen in return to theatre or readmission within 
90 days.  
 
The primary endpoint for this study was the overall length of stay in hospital as a surrogate 
marker for recovery. Choosing a primary end point for this study was not straightforward. 
There were several possible options all with their own limitations. We finally elected to 
choose length of stay for a number of reasons: Firstly, AWC were introduced in our 
Hepatobiliary and Transplant Surgery Department only a short period of time before 
commencing this study. This meant it was the only variable we had retrospective data for 
both groups to enable an accurate sample size calculation. Secondly, if we were to set a target 
that was a starting point with the length of stay seeming to be the choice in many other ERAS 
or AWC publications and would allow potential comparisons 114, 159. In addition, we 
anticipated that pain control and other outcomes would be largely comparable meaning  an 
unachievable sample size would be needed and not necessarily correlated with recovery. We 
also aimed to complement length of stay with HDU stay and days to meet ‘medically fit for 
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discharge’ data which aimed to eliminate some of the non-medical reasons associated with 
delayed discharge. 
 
With regards to the primary endpoint, despite AWC-PCA patients requiring less vasopressor 
support, less need for invasive monitoring and reduced requirement for IV fluids for fewer 
days, this did not translate into a reduced total length of stay when compared with EP. 
Although every effort was made to keep HDU admission to the minimal possible with a 
median of 1 day in each group (mean 1.3 vs. 1.8 in EP), no difference was seen when 
comparing length of HDU stay. However, it is worth noting that when vasoconstrictors were 
needed on POD 0 (54% for EP) or POD 1 (22% for EP) then the length of stay in HDU was 
significantly longer when compared to AWC-PCA (median POD 2.2 (p=0.004) and mean 2.6 in 
EP (p=<0.001)).  The HDU stay, medically fit for discharge and overall length of stay when 
comparing the EP group requiring vasopressors on Day 1 was also significantly longer than 
the AWC-PCA group (p=<0.001, 0.006 and 0.012 respectively). It is likely, however, that a 
much bigger cohort is needed to find a significant difference for the whole group.  As other 
groups have done, we also looked at the functional recovery time in an attempt to eliminate 
non-medical factors that would impact on overall LOS and again no differences were 
observed, unlike in previous studies 114, 159. The reasons for this are perhaps related to the 
sample size. The patients in this study had a median length of stay of 6 days whereas the 
dataset used to power this study had a median of 7 days (mean 9 days) this means that more 
patients are likely to be required to detect a difference.  The ERAS protocol itself was 
introduced in 2015 (immediately prior to this study commencing) and has helped to reduce 
the length of stay following liver resection from 9.2 (SD 8) days to a mean of 6.6 (SD 4.4) days 
in our unit (data not published). This is also likely to have impacted on the sample size 
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calculation. Despite not finding a reduced length of HDU, shorter overall stay or functional 
recovery with the use of AWC-PCA we were satisfied that recovery was comparable, and 
importantly not inferior, to those receiving EP. 
 
Importantly, the other outcomes for this study also did not demonstrate any inferiority in 
clinical outcomes when comparing AWC-PCA use with that of EP. Conversely, perhaps the 
most significant finding of this study, is the large difference in the proportion of patients 
requiring vasopressor support between the two groups, finding a large difference in favour 
of AWC-PCA. Hypotension as a consequence of the sympathetic blockade associated with 
thoracic epidural has been well described with both systolic and diastolic blood pressure, 
being reduced in healthy volunteers undergoing thoracic epidural 206. It has been reported 
that up to one third of non-obstetric patients receiving a thoracic epidural experience a 
significant reduction in blood pressure. It is estimated that the use of spinal or epidural 
analgesia brings about a 39-45% reduction in systolic blood pressure 207.  The development of 
hypotension in patients with thoracic epidural is multifactorial although is largely related to 
preganglionic sympathetic blockade. This decrease in sympathetic tone with unopposed 
parasympathetic tone leads to many of the changes to normal homeostasis and subsequent 
hypotension seen. The impact of thoracic epidural on the cardiovascular system causing 
hypotension can be broken down in to the following categories: 
1. Loss of cardio accelerator nerve function caused by blockade above the T5 level leads 
to removal of the chronotropic and inotropic influence of the sympathetic nervous 
system. Reduced venous return also contributes to bradycardia and subsequent 
reduced cardiac output causing blood pressure to fall. 
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2. There is limited evidence suggesting that the reduction in cardiac sympathetic outflow 
may affect myocardial contractility. However, much of the evidence regarding this is 
contradictory. 
3. The reduction in vasomotor tone associated with thoracic epidural is perhaps the main 
mechanism by which hypotension ensues. The nerve fibres controlling vasomotor 
tone arise from T5-L1 with blockade of this level leading to loss of vasoconstrictor 
sympathetic outflow leading to a ‘functional hypovolaemia’ due to peripheral 
vasodilatation. Some compensation can arise through a variety of mechanisms 
including vasoconstriction in the unblocked area, increased activity in unblocked 
splanchnic nerve fibres leading to release of catecholamines from the adrenal medulla 
as well as the renin-angiotensin and vasopressin systems 116, 208.   
 
The temptation with this ‘functional hypovolaemia’ is for volume loading with intravenous 
fluid. However, this should be avoided, particularly in hepatic resection. During the hepatic 
transection phase of liver resection, the central venous pressure is kept to a minimum to 
reduce intra-operative blood loss, with volume loading only occurring once this phase of 
surgery has been completed. For this reason, vasopressor support is commonly used 
intraoperatively to maintain adequate blood pressure. This study clearly showed a significant 
difference in intraoperative vasopressor requirements between the two groups with a greater 
proportion of patients being managed without vasopressor support or requiring only 
metaraminol boluses (rather than noradrenaline infusion) in the AWC-PCA group. This is  
presumably due to more profound hypotension related to the thoracic epidural. This effect is 
also seen on postoperative days 1 and 2 when significantly more patients also required 
infusion of noradrenaline, with this being the main reason the volume of intravenous fluid 
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was comparable at all time points. This requirement for increased vasopressor support can 
have several implications. The most obvious consequence is the need for invasive monitoring 
and at least level 2 (high dependency) care whilst vasopressors are required. This seems likely 
to impact on critical care length of stay and time to mobilise. In this study, when comparing 
all groups, no overall differences were noted in length of HDU stay or time to first mobilise 
although there was a non-significant trend towards a longer HDU stay in the EP group. As 
described previously, HDU stay was longer in the EP group requiring vasopressor support on 
day 1 than the AWC-PCA group (2.5 days versus 1 day, p= <0.001). However, it must be noted 
that this RCT was not powered to detect differences in length of HDU stay as given the small 
clinical difference between the groups a large, unfeasible, number of patients would have to 
be recruited. A reduction in critical care stay would have a beneficial effect on cost and also 
resource utilisation. According to the Welsh Consolidated Costing Return a ward bed costs on 
average £413 per night, a level 2 (HDU) bed £3857 per night and a level 3 (ICU) bed £1932 per 
night and with critical care bed occupancy rates running at 80% or higher any reduction in 
length of stay would be advantageous 209. Whilst a formal cost analysis was not undertaken 
as part of this study, it seems likely that epidural would be a more costly method of delivering 
pain relief. Thoracic epidural is also a labour-intensive method of delivering postoperative 
analgesia with numerous societies including the Royal College of Anaesthetists and 
Association of Anaesthetists of Great Britain and Ireland (AAGBI) guidelines recommending 
enhanced supervision of patients with thoracic epidural as best practice. It is also 
recommended that patients with thoracic epidural are monitored by an ‘acute pain team’ 
which should include a consultant anaesthetist, clinical nurse specialists and support from 
pharmacy services. Frequent monitoring of sensory and motor blockade, pain scores and 
routine haemodynamic parameters are also required of the ward-based nursing staff to 
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identify adverse events 210. Patients receiving wound catheters conversely require no 
additional monitoring although, in this study, still fell under the remit of the acute pain 
service. With increased use and familiarity, the majority of these patients could be managed 
solely by the parent team without the additional input from acute pain services. The insertion 
of a thoracic epidural also mandates the insertion of a urinary catheter to prevent urinary 
retention. The urinary catheter will need to remain in situ for as long as the epidural does. 
Conversely, with the use of AWC-PCA, the urinary catheter could be removed earlier as it is a 
regional technique without the blockade of the external urethral sphincter (S1-3) or detrusor 
muscle (S2-4). Whilst often underestimated, the insertion of a urinary catheter is associated 
with a 1-2% risk of infection, with the initial insertion rising to 3-7% for each day it remains in 
situ 211.   
 
Although pain scores were inferior in the AWC-PCA group on the evening following surgery, 
the afternoon of day 1 and the morning of day 2, pain scores were comparable at all time 
points beyond this. Whilst median pain scores were inferior at these time points, they were 
regarded as low (<4 on an 0-10 analgesic scale) at all time points in both groups and therefore 
these differences are unlikely to be clinically significant. As such, pain relief could be 
considered as largely comparable. The reason why there is no difference in pain scores on the 
morning of day 1 is unclear. It is possible that patients with failed thoracic epidurals were 
identified at this time and converted onto PCA. This would lead to pain scores being 
temporarily high in the EP group as those with failed epidural would only receive intravenous 
paracetamol until the epidural had been removed and opiate based PCA commenced.    
Intravenous opiate based PCA can provide effective post-operative analgesia although 
in high-doses is associated with nausea, vomiting, constipation, sedation and respiratory 
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depression 129. Similarly, epidural is associated with hypotension, the requirement for 
specialised anaesthetic input, significant failure rates and a small risk of devastating 
complications such as epidural haematoma or abscess 125, 210. Although rare, the incidence of 
permanent disability following epidural abscess/haematoma but also meningitis, nerve injury 
and cord ischaemia has been reported as 4.2 per 100, 000 212. This has led to the development 
of multi-modal analgesia regimes aimed at avoiding the problems associated with thoracic 
epidural and also minimising the use of opiates.  
 
Several studies have demonstrated that AWCs have an opioid-sparing effect when used in 
conjunction with PCA 161, 202, 213. This was confirmed in our study by comparing the epidural 
failure group (receiving PCA alone) to the AWC-PCA group. A significant reduction in the 
volume of IV morphine equivalent use was noted. This may impact on nausea and sedation 
particularly following liver resection when there is a temporary impairment of liver function 
as well as impaired opiate metabolism. Reduction in opiates may also be associated with 
improved return of bowel function with opiates known to have a constipating effect. 
However, the literature for this is contrasting and dependent on the definition used for 
‘return of bowel function’ 119, 214 - 216. In addition, epidural has been associated with a decrease 
in post-operative ileus which is thought to be related to the systemic absorption of local 
anaesthetic having a stimulating effect on the gastrointestinal tract 217, 218. Because AWCs also 
infiltrate local anaesthetic it is possible that this positive effect on return of gastrointestinal 
function would also be seen in this group. However, in our study, no difference was noted 
between the two groups when comparing return of gut function.  
More recently, there is emerging evidence that some cancers have high levels of mu opioid 
receptor. These when activated by opioid analgesics could lead to tumour growth and spread. 
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It therefore may become essential that as more is learned about this interaction every effort 
is made to restrict the quantity of opiates used in postoperative analgesic regimens 140, 219 - 
222. We feel it is feasible that in the future selected patients with a well-functioning AWC 
would require the PCA for only the initial 24 hours following surgery before this could be 
discontinued.                 
 
In this study, one patient was excluded due to the inability to insert an epidural whereas the 
insertion of AWC was always an option, even in patients with a high BMI or repeat abdominal 
surgery. In our experience, the main analgesia related complication experienced when AWC 
were inserted, was its accidental dislodgement (7% vs 20%, p=0.07). However, this event was 
far less likely when compared to EP and resulted in PCA only analgesia. Conversely the EP 
failure rate was 20% in our study, necessitating conversion to PCA, and is in keeping with 
other published series 114, 125. There is also concern regarding the use of EP following 
hepatectomy with the development of a coagulopathy leading to rare but potentially 
devastating complications such as epidural haematoma. In this series, unsurprisingly, no 
patients developed such complications. However, the removal of one patient’s EP was 
delayed by one day due to a deranged clotting profile. In addition, some patients may require 
some form of anticoagulation, such as following major vascular resection/reconstruction, 
following surgery where the use of EP may be a concern. 
 
In this study, epidural provided marginally better pain control than AWC-PCA but made 
overall patient management more challenging. In fact, although the difference in pain scores 
is statistically significant, this is unlikely to be of clinical significance with pain scores in both 
groups being regarded as low (median <4 on 11-point scale) at all time points 223. The use of 
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AWC as part of a multi-modal regime was also effective in reducing the requirement for IV 
opiates in this study. EP is a more invasive procedure, requires provision of vasopressors more 
frequently and therefore the need for central venous access, with a higher rate of failure. 
Ongoing management of patients with epidural is also resource-intensive, requiring 
involvement of acute pain teams and anaesthetists in the postoperative period 128. 
 
Another aspect of this study was an attempt to characterise and compare the impact, if any, 
of AWC-PCA and EP on the systemic inflammatory response following open liver resection. 
This study showed that IL-9 and MIP-1 levels significantly decreased with time in the AWC-
PCA group compared to the EP arm. There was no other significant difference in any of the 
other cytokine levels between the two groups. This would suggest that any impact that the 
two methods of analgesia have on the SIR is largely comparable and that AWC-PCA is not 
inferior.  
IL-9 levels in both groups fell from baseline level to reach their lowest level on Day 1 before 
increasing on Day 3. In the AWC-PCA group, the IL-9 level on day 3 did not reach the baseline 
level although in the EP group it rose significantly above it. IL-9 was first described in the late 
1980’s initially being described as a T cell and mast cell growth factor and called P40 224. 
However, further studies revealed that it was distinct from other T cell growth factors and it 
was renamed IL-9 because of its effects on myeloid and lymphoid cells. The major source of 
IL-9 is from T lymphocytes, with production being regulated by a series of cytokines and 
transcription factors. In particular, TGF- and IL-4 have been shown to strongly promote IL-9 
production from activated T cells, as has IL-2, whereas IFN- inhibits IL-9 production 225, 226. 
Studies have shown that IL-9 is produced by several CD4+ T cell groups including Th17 cells, 
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regulatory T cells and Th9 cells. IL-9 brings about its effects through a receptor complex 
composed of IL-9R and a common  chain. The receptor IL-9R has been shown to be 
expressed by several cell types including mast cells, macrophages as well as T cells, B cells and 
haematopoietic progenitor cells. This wide expression of the IL-9 receptor helps to explain 
the wide array of activity associated with IL-9, both pro- and anti-inflammatory 224, 227 – 229. 
Extensive studies have been done in recent years on the T cell subsets that produce IL-9, a 
cytokine that was initially thought to be a T cell- derived factor preferentially expressed by 
Th2 cells 230. The newly identified Th9 cells that predominantly produce IL-9 and IL-10 changed 
this conception. However, unlike Th2 cells, the Th9 cells do not exhibit any regulatory 
properties 231, 232, indicating that IL-9/IL-10-producing T cells are not regulatory T cells but 
effector T cells that induce tissue inflammation 233.  
MIP-1 is a member of the chemokine family. These are regulatory molecules involved in 
leucocyte maturation, traffic and homing of lymphocytes, as well as the development of 
lymphoid tissue 234. This group of cytokines have been shown to possess chemotactic activity 
for inflammatory and immune effector cells 235. The sources of MIP-1 have not been as well 
studied as those of MIP-1. However, it has been shown that monocytes produce high 
amounts of MIP-1 when stimulated with IL-7 or lipopolysaccharide. Production of MIP-1 is 
counteracted by IL-4, which reduces the level of MIP-1 mRNA expression. In addition, 
activated T cells and B cells that have been stimulated by antigen binding produce MIP-1 as 
do natural killer (NK) cells. MIP-1 has multiple roles, including augmenting adhesion of T 
lymphocytes to vascular adhesion molecule – 1 (VCAM-1), a potent chemo-attractor of 
lymphocytes and NK cells and modulation of cytokines from T lymphocytes 236. The cytokines 
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usually associated with a pro-inflammatory response such as IL-1, IL-6 and TNF- were all 
comparable between the two groups.  
In this study, the two groups were reasonably well matched although the EP group had a 
larger number of segments resected on average than the AWC-PCA group (median 4 vs 2, 
p=0.03) and there was a non-significant trend towards more serious complications (Clavien-
Dindo 3) in the AWC-PCA group (4 vs 0, p=0.083). It is already known that patients 
experiencing major post-operative complications have an increased systemic inflammatory 
response 172 - 174. As the AWC-PCA group in the cytokine analysis had a tendency towards more 
serious complications, it would be expected that the systemic inflammatory response in this 
cohort would be greater. In particular, levels of IL-6 and IL-8 are known to be significantly 
increased with major complications following surgery. Schwarz et al found a higher mean 
increase in levels of IL-2, and higher perioperative IL-5 in patients with severe complications 
following liver resection compared to those that did not 237.  This has been replicated in other 
surgical specialities, with some suggesting that postoperative levels of cytokines may have a 
better diagnostic value than the currently used leucocyte count and CRP levels 238. 
Overall, there was no major difference in cytokine response between the two groups. This is 
with the exception of IL-9 and MIP-1. However, as both of these cytokines have a pleiotropic 
effect and the major cytokines implicated in the systemic inflammatory response were 
comparable, it is unlikely that this finding is of clinical significance. It would appear from the 
findings of this study that there is no significant difference in the impact that either analgesic 
modality have on the systemic inflammatory response. When comparing the results of this 
study to the current literature, it would appear that the results are comparable although the 
levels of cytokines appear to be lower in our study.  
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There are several limitations to this study. An open label study was designed and thus may be 
a source of potential response bias. Whilst sham AWC or EP catheters can be employed 
previous studies have attempted their use with extreme difficulty and have counselled 
against their use 114. The use of length of stay as a primary endpoint also has its limitations 
with discharge from hospital being multifactorial. However, as AWC had only recently been 
introduced into the unit at the outset of this study it was one of the few variables we had 
retrospective data for to allow sample size calculation. As we also hypothesized that other 
outcomes would be largely comparable an unachievable sample size would be needed for 
these outcomes.  In addition, the sample size is insufficient to detect small differences in 
secondary outcomes between the two groups. Although we have not seen a shorter LOS in 
hospital, we did not find any justification to advocate the use of EP routinely in our patients 
and we believe that AWC-PCA provides a comparable alternative and better fits the 
philosophy of ERAS and should be incorporated into future protocols.  
 
The systemic inflammatory response analysis also has its limitations. This was a ‘single run’ 
experiment and therefore it is not possible to comment on the reliability and replicability of 
the results. However, this does help to eliminate inter-plate variation if multiple plates were 
being tested. The storage of samples for prolonged periods of time may have led to 
degradation of samples which could impact on cytokine levels. However, the protocol used 
for sample storage is well validated and it has been demonstrated that cytokine levels can be 
stable for up to 4 years in such conditions 239. The time taken from sample collection to 
processing and freezing also varied slightly from patient to patient. This could again have 
impacted on cytokine levels however samples in EDTA are stable at 4C for up to 4 hours 
before requiring centrifugation and all samples were collected, centrifuged and frozen within 
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this time-frame 240. The samples were also run in singlet only although standards and blanks 
were run in duplicate to ensure precision of the concentration curve. This unfortunately 
doesn’t allow for calculation of sample variation and therefore no comment can be given 
about the precision of the assay. Whilst samples were collected and stored in triplicate due 
to the size of the plate, number of patients recruited and the cost of the materials required 
for this analysis it wasn’t feasible to run this study in duplicate/triplicate. Whilst this aspect 
of the study is not internally validated it does provide some reassurance that there is no major 
difference between the two techniques on the systemic inflammatory response.  
 
There are many potential avenues for further work. Further large volume, multicentre 
randomised controlled trials comparing AWC-PCA as a multimodal regime to thoracic epidural 
or intrathecal morphine may help to demonstrate reduced length of stay particularly on HDU. 
It is possible that such studies would also identify further differences in secondary outcomes 
that this study was not powered to find. In addition, the majority of ERAS pathways are based 
on low quality evidence. High quality studies are needed to confirm the benefit of ERAS in 
hepatobiliary surgery and to further develop the individual components of such pathways.  
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Conclusion 
AWC-PCA was comparable to EP with regards to overall length of stay following open liver 
resection. The use of AWC-PCA was associated with reduced treatment failure and a reduced 
vasopressor requirement than EP up to two days post-operatively, whilst providing pain relief 
that was acceptable and comparable morbidity. There was no difference in systemic 
inflammatory response. Whilst the use of AWC-PCA did not translate into a shorter LOS in this 
study, it simplified patient management after OLR. We therefore found no reason to routinely 
incorporate EP into ERAS protocols following OLR and have subsequently abandoned its 
routine use. AWC-PCA provides an acceptable alternative as part of a multimodal regime and 
we believe further ERAS protocols should incorporate its use. Further randomized studies 
should be aimed at developing other aspects of ERAS protocols following liver surgery.  
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Appendices 
A. – ERAS Protocol 
 
Day 0 - Pre surgery/Surgery 
  
- Admission either morning of surgery or day before 
- No routine pre-medication (unless very anxious) 
- Anaesthetic 
o Anaesthetic (Appendix C) 
o Epidural Group Only(Appendix D) 
o Pre-op antibiotics 
▪ 1.2g IV Augmentin 
▪ Penicillin Allergy: Gentamicin 2mg/kg + Metronidazole 500mg 
IV 
o Intra-op antiemetic: 8mg dexamethasone 
o Central line 
o Arterial line 
o Urinary catheter 
o Fluid Protocol - during the liver resection phase a low CVP (central 
venous pressure) of 0-5mmHg will be maintained to minimise venous 
bleeding. Following liver resection Hartmann’s solution will be 
administered to maintain a CVP of 8-12mmHg 
o Blood losses replaced at 1:1 ratio with volplex  
o Patient warming with ‘bear hugger’ 
- Surgical 
o Incision 
o No routine NG tube. NG sited intra-operatively will be removed at the 
end of surgery 
o No routine use of drains  
o Wound catheter Group Only (Appendix E) 
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Day 0 - Post Surgery (evening of surgery) 
- All patients will receive regular 1g Paracetamol (unless stated in post op 
instructions) 
- All patients will receive 4mg Ondansetron QDS 
- All patients will receive 15ml Lactulose BD  
- Routine VTE prophylaxis (Tinzaparin/Enoxaparin (impaired renal function) and 
TED stockings (unless contraindicated)) as per LTHT protocol 
- Oxygen as required to maintain Sats >94% 
- Fluid Protocol - In the postoperative period patients would be started on 
maintenance fluid with Hartmann’s solution @ 80ml/hr. Fluid challenges of 
crystalloid up to 200ml would be used to achieve desired CVP/ urine output 
(0.5ml/kg/min).  
- Epidural/Wound catheter as per protocol 
- Patient will be encouraged to sit out for 2hours on the evening following 
surgery 
- Resume free fluids on evening following surgery 
- Pain score (rest and on movement) at 2 and 6hr from arriving on HDU 
- Sedation score at 2 and 6hr from arriving on HDU 
- Nausea score at 2 and 6hr from arriving on HDU 
- Peak flow at 6hr from arriving on HDU 
 
Day 1 
- Resume normal diet 
- Stop IVI if > 1litre oral intake. Maintenance with Hartmann’s 40ml/hr if less 
than 1litre intake 
- Initiate oral analgesic regime (1g Paracetamol QDS, 400mg Ibuprofen TDS), 
- Arterial line out (if not clinically required) 
- Central line out (if not clinically required) 
- Continue Epidural and wound catheter/PCA as per protocol 
- Sit out in chair for >6hours 
- Record pain/sedation/nausea scores, peak flow, bowels opened 
- Record total daily volumes of IVI, vasopressors, opioids 
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- Assess against criteria to discharge from HDU twice daily 
 
Day 2 
- Sit out for >8hours 
- Initiate oral analgesic regime (1g Paracetamol QDS, 400mg Ibuprofen TDS), 
Record pain/sedation/nausea scores, peak flow, bowels opened 
- Record total daily volumes of IVI, vasopressors, opioids 
- Assess against criteria to discharge from HDU twice daily (Appendix B) 
- PCA can be removed if not used. The addition of Codeine 30 mg/qds (if not 50-
100mg Tramadol QDS) when PCA stopped 
 
Day 3 (60 hours from end of surgery) 
- Trial of stopping/Remove epidural (if INR <1.5) and wound catheters  
- Remove PCA if still in place. 
- Remove urinary catheter if not clinically required. 
- 1g Paracetamol QDS and 400mg Ibuprofen TDS 
- Codeine 30 mg/qds (if not 50-100mg Tramadol QDS) 
-  5-10mg Oral morphine as required for breakthrough pain 
- If significant difficulties controlling pain, PCA might be recommenced. 
- Increase mobilisation 
- Encourage oral intake 
- Assess against criteria to discharge from HDU twice daily (Appendix B) 
- Record pain/sedation/nausea scores, peak flow, bowels opened 
- Record total daily volumes of IVI, vasopressors, opioids 
 
Day 4 onwards 
- Assess against criteria to discharge from hospital twice daily (Appendix B) 
- Mobilise 
- Increase oral intake 
- Oral analgesia: Paracetamol 1 gr QDS and Codeine 30 mg/qds (if not 50-100mg 
Tramadol QDS). Ibuprofen will be stopped. 
- Record pain/sedation/nausea scores, peak flow, bowels opened until Day 5 
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4-6 Weeks Post Discharge 
- routine clinical review in OPD 
- Patient satisfaction questionnaire 
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Centre Number: 1 
Study Number: 14/YH/1267 
Patient Identification Number for this trial: 
CONSENT FORM 
Title of Project: Epidural versus Wound Catheters following Open Liver Resection 
 
Name of Researcher: Mr E. Hidalgo 
 
Please initial 
all boxes  
1. I confirm that I have read and understand the information sheet dated 
09/02/2015 (version 1.7) for the above study.  I have had the opportunity 
to consider the information, ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care 
or legal rights being affected. 
 
3. I agree to take part in the above study. 
 
4. I understand that sections of my medical notes and data may be looked 
at by responsible individuals from the NHS Trust or regulatory authorities 
where it is relevant to my taking part in this research'. I give my 
permission for these individuals to have access to my records  
 
 
            
Name of Participant   Date    Signature 
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Patient Information Leaflet: 
 
Epidural Analgesia vs Wound Catheters Following Open Liver Resection. 
14/YH/1267 
 
We would like to invite you to take part in a research study. Before you decide you 
need to understand why the research is being done and what it would involve for you. 
Please take time to read the following information carefully. Feel free to discuss the 
study with family and friends if you wish. Please ask us if there is anything that is not 
clear or if you would like more information. 
 
What is the purpose of the study? 
At present patients undergoing an open liver resection at SJUH mainly receive an 
epidural for postoperative pain relief. This involves putting a small tube into your back 
to numb you from your chest to your feet. Whilst the pain relief provided can be good 
there are a number of side effects that can occur with epidural analgesia. In addition, 
epidural analgesia does not work well up to 30% of the time. We propose using a new 
combination of analgesia that has already been shown to be effective following other 
surgery. This involves placing wound catheters (small tubes placed into the wound 
during your operation) which continually infuse the wound with local anaesthetic. In 
addition to this you will have a PCA button (patient controlled analgesia) to give you 
additional pain killers as and when you require them. We want to investigate how the 
recovery between these two methods of analgesia varies and in particular if this new 
method of analgesia leads to a quicker discharge from hospital.  
 
Why have I been invited? 
All adults who are scheduled to have an open liver resection at SJUH have been invited 
to take part.  
 
Do I have to take part? 
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No. Your participation in this study is entirely voluntary. If you decide that you do not 
want to take part your care will not be affected in any way. 
  
What will happen if I take part? 
You will be approached on the morning of surgery to sign a form confirming 
you want to take part in the study. You will then be randomly assigned to receive 
either an epidural or the combination of analgesia. The epidural will be placed whilst 
you are awake and involves a small plastic tube being placed in your back. Medication 
is delivered via this to block the nerve signals involved in pain. The combination of 
analgesia will be placed whilst you are asleep. This involves placing 2 plastic tubes 
within the muscles that make up the wall of your abdomen. A pump is attached to 
these which will deliver medication to block pain signals. The PCA will be connected 
to your drip and gives you additional pain relief when you press the button. You 
cannot choose which method you want to receive.  
 In the days following surgery both groups will receive exactly the same care. 60 hours 
following the operation both groups will have either the epidural or combination of 
analgesia removed. Both groups will then receive the same analgesic regime. At set 
points during your recovery we will record various scores: 
 
Peak Flow - breathing into a small plastic tube as hard and fast as possible. This will 
be measured once before your operation and once a day after your operation up to 
day 5 and gives an indication of how comfortable you are. 
Pain Score - you are asked to rate your pain from 1- 10 on a scale. This tells us how 
effective your pain relief is. This is recorded at 2 and 6 hours post operation, twice a 
day on postoperative days 1 and 2 and then once a day on post-operative days 3, 4 
and 5. 
Nausea Score - a scale from 1 - 3 looking at nauseous you feel as some of the side 
effects of pain killers can cause this. This is recorded twice a day up to day 5. 
Sedation Score - A scale from 1 - 3 looking at how drowsy you are as some of the side 
effects of pain killers can cause this. This is recorded twice a day up to day 5. 
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These scores are taken more frequently than someone receiving routine care. 
Following your discharge from hospital you will be seen in your routine outpatient 
follow up appointment and asked to complete a questionnaire. This usually happens 
between 4 and 6 weeks after surgery. This will be the end of the study and you will 
then receive routine follow up.  
 
What are the disadvantages to taking part? 
There will be no effect on your surgery. The pain relief with the wound catheters may 
not be as effective as the epidural although current evidence suggests they are similar.  
 
What are the benefits to taking part? 
Your recovery following your surgery may be enhanced. The length of time you stay 
in hospital may be shorter if you are allocated to the wound catheter group.  This study 
may help to improve care for patients undergoing open liver resection in the future. 
 
Will my taking part be kept confidential? 
All information kept as part of the study will be kept in the strictest confidence. Only 
members of the medical team looking after you will have access to your specific 
information. 
 
What will happen if I don’t want to take part? 
It is your decision whether you want to take part or not. If you decide that you do not 
want to take part then your care will not be affected. If you decide that you do not 
want to take part you may receive an epidural as part of your care. 
 
What will happen if I decide I want to stop my participation in the study? 
You can decide to withdraw from the study at any point. Your care will be unaffected. 
Information collected up to your withdrawal from the study will be kept. No further 
information will be kept or stored after your withdrawal. You will continue to receive 
routine follow-up following your withdrawal from the study. 
 
What will happen to the results of the study? 
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We will look to publish the results of the study in medical journals or at conferences. 
You will not be identifiable in this publication. If you would like to know the results, 
we can send you a report when the study is completed. 
 
Who is organising the study? 
The study is being organised by a combination of surgeons and anaesthetists who 
work at the Leeds Teaching Hospitals. The lead surgeon for this study is Mr Ernest 
Hidalgo. This study has been reviewed and approved by The Bradford Leeds Research 
Ethics Committee. 
 
Contact for Complaints or Independent advice: 
If you feel like you would like advice from someone independent to the study please 
contact the patient advice and liaison service (PALS): 
Tel: 0113 2066261 
Email: patientexperience.leedsth@nhs.net  
 
Contact for further information: 
If you would like more information about the study then please contact: 
 
Mr Richard Bell     
Clinical Research Fellow 
Email: Richard.bell6@nhs.net 
Tel: 0113 20668378 
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RCT comparing epidural analgesia vs. continuous local anaesthetic infiltration via 
wound catheter and IV opioid PCA in open liver resection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contact details for Trial personnel 
Mr Richard Bell (Clinical Research Fellow)       
Mr Razdy Igasan - ERAS-CNS 
Mr Ernest Hidalgo (Consultant Surgeon)                      
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Patient Care Pathway 
 
         
       
 
 
Pre-operation  
-Pre-op drinks x 6        □ 
  
-Patient warming         
 
Day 0 – Pre-op 
-Consented          
-Baseline peak flow         
-Randomisation at theatre briefing       
 
□ 
□ 
□ 
□ 
Surgery + Wound Catheter/Epidural Insertion 
 
Day 0 – Post-op 
-Oral Fluids          
-Pain, Nausea and Sedation scores       
-Regular IV Ondansetron 4mg TDS      
-Regular paracetamol 1g QDS, 400mg Ibuprofen TDS (unless contraindicated)   
-Omeprazole 20mg OD IV/PO        
-Tinzaparin + TEDS (unless specified otherwise)       
-Hartmanns 80ml/hr maintenance +/- Volplex (as required)    
-Oxygen as required (to maintain sats >94%)      
 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
Day 1 
-Normal diet and fluids         
-Fresubin 200ml TDS         
-Lactulose 10ml BD         
-Omeprazole 20mg OD         
-Regular PO Paracetamol 1g QDS, 400mg Ibuprofen TDS (unless contraindicated)   
-Mobilize/Sit out for >6 hours        
-Pain, nausea and sedation scores (morning and afternoon)     
-Peak flow (morning and afternoon)        
-Stop IVI if PO intake >1 litre (maintenance as above if required)     
-Hartmanns 80ml/hr if IVI still required       
-Arterial line/Central line/Urinary catheter/drain out (if appropriate)    
-Assess if fit for discharge from HDU       
-Leave Epidural/Wound Catheters       
 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
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Day 2 
-Normal diet and fluid          
-Mobilise out of bed >8 hours        
-Pain, nausea and sedation scores (morning and afternoon)     
-Peak flow (morning and afternoon)        
-Arterial line/Central line/Urinary catheter/Drain out (if appropriate)    
-Trial of stopping PCA         
-Codeine 30-60mg QDS/Tramadol 50-100mg QDS (if PCA discontinued)   
-Oral morphine 10mg 2-4 hrly PRN (if PCA discontinued)     
-Leave Epidural/Wound Catheters        
-Assess if fit for discharge from HDU        
 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
Day 3 
-REMOVE WOUND CATHETER/EPIDURAL      
-Stop PCA          
-Arterial line/Central line/Urinary catheter/Drain out (if appropriate)    
-Pain, nausea and sedation scores (morning and afternoon)     
-Peak flow (morning and afternoon)        
-Codeine 30-60mg QDS/Tramadol 50-100mg QDS (when PCA discontinued)  
-Oral morphine 10mg 2-4 hrly PRN (when PCA discontinued)    
-Assess if fit for discharge from HDU/Hospital       
 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
□ 
Day 4 
-Pain, nausea and sedation scores (morning and afternoon)     
-Lines/Catheter/Drain out (if appropriate)      
-Peak flow (morning and afternoon)        
-Assess if fit for discharge from HDU/Hospital      
 
□ 
□ 
□ 
□ 
Day 5 
-Pain, nausea and sedation scores (morning and afternoon)     
-Peak flow (morning and afternoon)        
-Assess if fit for discharge         
 
□ 
□ 
□ 
Day 6 
-Pain, nausea and sedation scores (morning and afternoon)     
-Peak flow (morning and afternoon)        
-Assess if fit for discharge         
 
□ 
□ 
□ 
Clinic  
-Patient satisfaction questionnaire       □ 
  144 
Data Collection Proforma 
 
Please Document any deviation from the protocol below: 
_____________________________________________________________________
_____________________________________________________________________ 
Pre-Op  
Baseline Peak-flow - 
_______________________________________________________________________________
___ 
Randomisation Group:   Epidural    /   Wound Catheter  (please circle) 
 
Surgical/Anaesthetic 
Date of Birth - ___________________________________ 
Gender – M  /   F 
BMI - _____________________________________________ 
ASA – I   /   II   /   III   /   IV 
Diagnosis - _______________________________________ 
Previous Abdominal Surgery – Yes   /   No  Previous Liver Surgery -   Yes   /    No 
Previous Surgery - 
_______________________________________________________________________________
_ 
Operation - 
_______________________________________________________________________________
_________ 
Major   /   Minor     (Please circle)  Number of segments resected - _________________ 
Date of Operation:_________________________________________ 
Time into Anaesthetic Room: _____________:________________ 
Time at Knife to Skin: ______________:________________________ 
Time at Completion of Closure: ___________:________________ 
Wound Length (cm): ________________________________________ 
Wound Shape:   Reverse L    /    Reverse J    /    Mercedes     
Total Volume of Intra-operative Fluid (ml):___________________________________ 
Total Opioid: 
_____________________________________________________________________ 
Total volume of vasopressor (mg): _________________________Vasopressor used: 
___________________ 
 
Other: 
  145 
 
Day 0 – Until 8am 
Date: _________________________________ 
Pain Score (17:00):      0          1          2          3          4          5          6          7          8          9          
10  
Nausea Score:  0  1  2  3 
Sedation Score:  0  1  2  3 
Peak Flow:
 ________________________________________________________________________
_________ 
 
 
Day 1 – 8am – 8am 
Date: ________________________________ 
Pain Score (08:00-09:00):      0         1         2         3         4         5         6         7         8         9         
10  
Nausea Score (08:00-09:00): 0  1  2  3 
Sedation Score (08:00-09:00): 0  1  2  3 
Peak Flow (08:00-09:00):
 ____________________________________________________________________ 
 
Pain Score (13:00-17:00):      0         1         2         3         4         5         6         7         8         9         
10  
Nausea Score (13:00-17:00): 0  1  2  3 
Sedation Score (13:00-17:00): 0  1  2  3 
Peak Flow (13:00-17:00):
 ____________________________________________________________________ 
 
Total Volume of IV Fluid (ml): 
__________________________________________________________________ 
Total Vasopressor Requirement (mg): 
_________________________________________________________ 
Total Opioid Used (mg): 
_________________________________________________________________________ 
Total Tries/Number Good: _______________________________ 
/_____________________________________ 
Total Analgesia Given: 
_______________________________________________________________________________
_ 
_______________________________________________________________________________
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Please document any deviation from the protocol or complications below: 
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________ 
Day 2 – 8am – 8am 
Date: ________________________________ 
Pain Score (08:00-09:00):      0         1         2         3         4         5         6         7         8         9         
10  
Nausea Score (08:00-09:00): 0  1  2  3 
Sedation Score (08:00-09:00): 0  1  2  3 
Peak Flow (08:00-09:00):
 ____________________________________________________________________ 
 
Pain Score (13:00-17:00):      0         1         2         3         4         5         6         7         8         9         
10  
Nausea Score (13:00-17:00): 0  1  2  3 
Sedation Score (13:00-17:00): 0  1  2  3 
Peak Flow (13:00-17:00):
 ____________________________________________________________________ 
 
Total Volume of IV Fluid (ml): 
__________________________________________________________________ 
Total Vasopressor Requirement (mg): 
_________________________________________________________ 
Total Opioid Used (mg): 
_________________________________________________________________________ 
Total Tries/Number Good: _______________________________ 
/_____________________________________ 
Total Analgesia Given: 
_______________________________________________________________________________
_ 
_______________________________________________________________________________
_______________________________________________________________________________
________________________________________________________ 
Bowels Open:  Yes / No  (please circle) 
Time Sat out of bed: _____________________:_________________________________ 
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Please document any deviation from the protocol or complications below: 
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________ 
Day 3 – 8am – 8am 
Date: ________________________________ 
Pain Score (08:00-09:00):      0         1         2         3         4         5         6         7         8         9         
10  
Nausea Score (08:00-09:00): 0  1  2  3 
Sedation Score (08:00-09:00): 0  1  2  3 
Peak Flow (08:00-09:00):
 ____________________________________________________________________ 
 
Pain Score (13:00-17:00):      0         1         2         3         4         5         6         7         8         9         
10  
Nausea Score (13:00-17:00): 0  1  2  3 
Sedation Score (13:00-17:00): 0  1  2  3 
Peak Flow (13:00-17:00):
 ____________________________________________________________________ 
 
Total Volume of IV Fluid (ml): 
__________________________________________________________________ 
Total Vasopressor Requirement (mg): 
_________________________________________________________ 
Total Opioid Used (mg): 
_________________________________________________________________________ 
Total Tries/Number Good: _______________________________ 
/_____________________________________ 
Total Analgesia Given: 
_______________________________________________________________________________
_ 
_______________________________________________________________________________
_______________________________________________________________________________
________________________________________________________ 
Bowels Open:  Yes / No  (please circle) 
Time Sat out of bed: _____________________:_________________________________ 
Fit for Discharge from HDU: Yes   /   No Time Discharged: 
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Please document any deviation from the protocol or complications below: 
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________ 
Day 4 – 8am – 8am 
Date: ________________________________ 
Pain Score (08:00-09:00):      0         1         2         3         4         5         6         7         8         9         
10  
Nausea Score (08:00-09:00): 0  1  2  3 
Sedation Score (08:00-09:00): 0  1  2  3 
Peak Flow (08:00-09:00):
 ____________________________________________________________________ 
 
Pain Score (13:00-17:00):      0         1         2         3         4         5         6         7         8         9         
10  
Nausea Score (13:00-17:00): 0  1  2  3 
Sedation Score (13:00-17:00): 0  1  2  3 
Peak Flow (13:00-17:00):
 ____________________________________________________________________ 
 
Total Volume of IV Fluid (ml): 
__________________________________________________________________ 
Total Opioid Used (mg): 
_________________________________________________________________________ 
Total Tries/Number Good: _______________________________ 
/_____________________________________ 
Total Analgesia Given: 
_______________________________________________________________________________
_ 
_______________________________________________________________________________
_______________________________________________________________________________
________________________________________________________ 
Bowels Open:  Yes / No  (please circle) 
Time Sat out of bed: _____________________:_________________________________ 
Fit for Discharge from HDU/Hospital: Yes   /   No Time Discharged: 
_______:________ 
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Please document any deviation from the protocol or complications below: 
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________ 
Day 5 – 8am – 8am 
Date: ________________________________ 
Pain Score (08:00-09:00):      0         1         2         3         4         5         6         7         8         9         
10  
Nausea Score (08:00-09:00): 0  1  2  3 
Sedation Score (08:00-09:00): 0  1  2  3 
Peak Flow (08:00-09:00):
 ____________________________________________________________________ 
 
Pain Score (13:00-17:00):      0         1         2         3         4         5         6         7         8         9         
10  
Nausea Score (13:00-17:00): 0  1  2  3 
Sedation Score (13:00-17:00): 0  1  2  3 
Peak Flow (13:00-17:00):
 ____________________________________________________________________ 
 
Total Volume of IV Fluid (ml): 
__________________________________________________________________ 
Total Opioid Used (mg): 
_________________________________________________________________________ 
Total Tries/Number Good: _______________________________ 
/_____________________________________ 
Total Analgesia Given: 
_______________________________________________________________________________
_ 
___ ___ ___ __ __ ___ ___ ___ ___ ___ ___ __ __
_______________________________________________________________________________
________________________________________________________ 
Bowels Open:  Yes / No  (please circle) 
Time Sat out of bed: _____________________:_________________________________ 
Fit for Discharge from HDU/Hospital: Yes   /   No Time Discharged: 
_______:________ 
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Please document any deviation from the protocol or complications below: 
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
Day 6 – 8am – 8am 
Date: ________________________________ 
Pain Score (08:00-09:00):      0         1         2         3         4         5         6         7         8         9         
10  
Nausea Score (08:00-09:00): 0  1  2  3 
Sedation Score (08:00-09:00): 0  1  2  3 
Peak Flow (08:00-09:00):
 ____________________________________________________________________ 
 
Pain Score (13:00-17:00):      0         1         2         3         4         5         6         7         8         9         
10  
Nausea Score (13:00-17:00): 0  1  2  3 
Sedation Score (13:00-17:00): 0  1  2  3 
Peak Flow (13:00-17:00):
 ____________________________________________________________________ 
 
Total Volume of IV Fluid (ml): 
__________________________________________________________________ 
Total Opioid Used (mg): 
_________________________________________________________________________ 
Total Tries/Number Good: _______________________________ 
/_____________________________________ 
Total Analgesia Given: 
_______________________________________________________________________________
_ 
_______________________________________________________________________________
_______________________________________________________________________________
________________________________________________________ 
Bowels Open:  Yes / No  (please circle) 
Time Sat out of bed: _____________________:_________________________________ 
Fit for Discharge from HDU/Hospital: Yes   /   No Time Discharged: 
_______:________ 
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Clinic Review 
Wound Complications: 
_______________________________________________________________________________
__ 
Other Complications: 
_______________________________________________________________________________
___ 
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_____ 
Patient Satisfaction Questionnaire: 
 
END OF TRIAL 
 
 
 
 
HDU Discharge Criteria 
• Respiratory 
o Requiring less than 40% Oxygen 
o Respiratory rate <20 >10 
o SpO2 >94% 
• Cardiovascular 
o No CVP/invasive BP monitoring required 
o ECG monitoring not required 
o No vasopressor requirements or large boluses of fluid 
• Renal 
o Stable renal function on biochemistry 
o Urine output >25ml/hr 
• Analgesia 
o Pain control adequate with current method of analgesia 
• General 
o Able to mobilise out of bed 
 
Discharge Home Criteria: 
• Adequate pain control on oral analgesia. 
• Eating and drinking with no requirement for intravenous fluids in previous 24 
hours. 
• Independently mobile (can mobilise independently to toilet). 
• Able to perform activities of daily living (washing, dressing) without help from 
nursing staff. 
• Blood tests returning to normal range. 
• Patient willing to go home. 
 
Medically Fit for Discharge Date: ________________________________ Time: 
___________:______________ 
Actual Discharge Date: ___________________________ 
Time:_________________:_____________________________ 
Reason for delay (if any): 
______________________________________________________________________________ 
_______________________________________________________________________________
_____________________________ 
  152 
Abstracts/Presentations 
 
1.  European – African Hepato-Pancreato-Biliary Association Meeting. Mainz, Germany. 2017.    
Randomized Clinical Trial of Abdominal Wound Catheters (AWC) versus Epidural Analgesia 
(EP) following Open Liver Resection (OLR): An Interim Analysis. Richard Bell*, Julie Jeffery, 
Deesa Ward, Peter Lodge, Ernest Hidalgo. 
2.  A Systematic Review and Meta-analysis of Epidural versus Local Anaesthetic Infiltration via 
Wound Catheters in Open Liver Resection. R. Bell*, S. Pandanaboyana, I. Wijetunga, E. 
Hidalgo, R. Prasad. BJS 2015; 102 (S1): 127–301  
3. International  Hepato-Pancreato-Biliary Association Meeting. Geneva, Switzerland. 2018.    
Randomized Clinical Trial of Abdominal Wound Catheters versus Epidural Analgesia following 
Open Liver Resection. Richard Bell*, Julie Jeffery, Deesa Ward, Giles Toogood, Peter Lodge, 
Krishna Rao, Sharmeen Lotia, Ernest Hidalgo. 
